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Complement systemMuch evidence is available that inﬂammation contributes to the development of neurodegenerative diseases
such as Alzheimer's disease, Parkinson's disease and Huntington's disease. Our review investigates how well
current mouse models reﬂect this aspect of the pathogenesis.
Transgenic models of AD have been available for several years and are the most extensively studied.
Modulation of cytokine levels, activation of microglia and, to a lesser extent, activation of the complement
system have been reported. Mouse models of PD and HD so far show less evidence for the involvement of
inﬂammation.
An increasing number of transgenic mouse strains is being created to model human neurodegenerative
diseases. A perfect model should reﬂect all aspects of a disease. It is important to evaluate continuously the
models for their match with the human disease and reevaluate them in light of new ﬁndings in human
patients.
Although none of the transgenic mouse models recapitulates all aspects of the human disorder they
represent, all models have provided valuable information on basic molecular pathways. In particular, the
mouse models of Alzheimer disease have also led to the development of new therapeutic strategies such as
vaccination and modulation of microglial activity.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The perfect animal model of a human disorder should reﬂect (i)
the symptoms, (ii) the lesions and (iii) the causes [1]. Here we will
review how transgenic mouse models meet these criteria with special
consideration of the inﬂammation hypothesis. We discuss the role and
modulation of inﬂammatory processes in these models.
The inﬂammation hypothesis proposes that a chronic inﬂamma-
tory response occurs in neurodegenerative disorders such as
Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's
disease (HD), and that this response exacerbates the characteristic
neurodegeneration. Several ﬁndings support the hypothesis for AD
and to some extent for PD and HD: (i) markers of inﬂammation are
elevated in postmortem brain tissue (gliosis, proinﬂammatory
cytokines, complement activation); (ii) epidemiological studies
indicate that long-term use of non-steroidal anti-inﬂammatory
drugs (NSAIDs) lowers the risk of disease; (iii) DNA polymorphism
of some cytokines and acute phase proteins modulates the risk; and
(iv) animal and cell culture models show that modulation of
inﬂammation is effective in curbing the disease process (reviewed
in [2–4]). When involvement of inﬂammation in these disorders was
ﬁrst discovered, it was viewed solely as a detrimental factor. More.
ll rights reserved.recently it has been suggested that certain aspects of the immune
response can play a positive role in regeneration and clearance of
pathological aggregates, creating great interest in the possible
modulation of immune responses in order to obtain beneﬁcial effects
[5–7].
2. Transgenic mouse models of Alzheimer's disease
In AD, a disturbance of beta amyloid protein (Aβ) metabolism
leads to the formation of soluble oligomers and larger, insoluble
aggregates. It is now thought that the oligomers themselves may be
neurotoxic, causing synapse loss and neuronal degeneration, accom-
panied by aberrant tau phosphorylation and formation of neuroﬁ-
brillary tangles (NFT). Transgenic mouse models of AD have been
created by introducing to the mouse genome mutated forms of the
human amyloid precursor protein (APP) or the presenilin 1 (PS1)
gene found in familial AD cases (sporadic AD is not connected with
such mutations). Introduction of wild-type forms of APP and PS1 as
found in normals and non-familial AD cases does not result in mouse
pathology. The mice expressing pathological human mutant proteins
readily develop Aβ deposits, show behavioral deﬁcits, and display
some aberrant tau-phosphorylation, even though very little neuronal
death occurs (for recent reviews see: [1,8,9]). Neuroﬁbrillary tangles
(one of the major pathological hallmarks of AD) are not found in
these mouse strains. Different transgenic models with additional
890 C. Schwab et al. / Biochimica et Biophysica Acta 1802 (2010) 889–902pathological tau mutations have been created to mimic this aspect of
AD [10]. Even though these tau mutations cause other tauopathies,
they are not associated with AD.
2.1. Complement activation in AD mouse models
The complement system is a major component of the body's
immune defense. It is an ancient and highly conserved system which
is a key component of the innate defense against microbes and other
infections. It is also a key component of the adaptive immune system
clearing antigen-antibody complexes. In addition, it is involved in
clearance of damaged tissue and necrotic cells of the body itself. The
complement pathways are cascades of proteins which are sequen-
tially cleaved and terminally assembled. They can be activated via
the classical pathway initiated by C1q binding, the alternative
pathway, starting with activation of C3, or the lectin pathway. Full
complement activation results in formation of the membrane attack
complex (MAC or C5b-9) consisting of the assembly of the proteins
C5b through C9. MAC inserts into membranes and lyses cells. The
complement system is a potent mechanism and is tightly regulated
by inhibitors such as C1 inhibitor, factor H and C4b-binding protein.
Activation of the complement system results in opsonization of
targets for phagocytosis, production of pro-inﬂammatory anaphyla-
toxins (C5a, C3a) and in lysis of cells. For a review of the complement
system see [11].
Complement activation in AD was ﬁrst described more than two
decades ago (for review see [12,13]). This activation likely occurs as
an attempt to clear toxic protein aggregates and debris of dying cells.
Complement activation attracts microglia, promotes secretion of
inﬂammatory cytokines and induces neuronal damage via MAC and
free radicals, contributing to the pathogenesis of AD [3]. It has been
demonstrated that Aβ is a powerful activator of complement. It binds
to C1q [14,15], initiating the classical pathway of complement
activation. Aβ also activates the alternative pathway by formation of
complexes with activation products of C3 [16]. In AD complement is
activated fully [17,18] and early [19] in the disease process. With the
exception of C4b binding protein [20], expression of complement
inhibitors is deﬁcient and the complement system activation is not
adequately controlled [19,21].
Markers of complement activation have also been detected in
several AD mouse models. In a triple mutation model of cerebral
amyloid angiopathy (SwDI; Dutch E693Q, Iowa D694N and Swedish
K670N/M671Lmutations), Fan et al. [22] described that mRNAs of the
early complement components C1q and C3were upregulated. C1q, C3,
and C4 protein levels were also elevated in Western blots. In
immunostaining, the complement proteins colocalized with ﬁbrillary
Aβ deposits and microglia. Matsuoka and colleagues [23] showed that
mouse C1q strongly colocalized with ﬁbrillary Aβ, and was also up-
regulated in some plaque-associatedmicroglia in PS/APPmice. Failure
to detect robust C1q binding to plaques in another report [24] may be
due to differences between transgenic strains or the anti-C1q
antibodies used. A more recent study found C1q deposition to
increase with age in Tg2576 mice [25].
C1q knock-out mice (Q−/−) are not able to activate the classical
complement pathway. Crossing this strain with Tg2576 or APP/PS1
mice reduced neuropathology as demonstrated by a decreased loss of
the presynaptic marker synaptophysin and diminished glia activa-
tion, while the plaque load remained unchanged [26]. In the double-
transgenic strain (APPQ−/−), Zhou and colleagues [25] reported
reduced C4 expression and upregulated C3 expression, suggesting
that components of the alternative complement pathway (C3b, C3a,
or C5a) could have a neuroprotective function. However, a recent
study showed that C5a may actually play a detrimental role [27].
Additional evidence for a neuroprotective function of C3 of the
alternative pathway was provided by Maier et al. [28] who found
that C3 deﬁciency increased Aβ plaque formation and neuronal lossin APP mice which were crossed with C3 knock-out mice. The
phenotype of microglia was switched towards an increase in CD45
expressing cells.
Overexpression of the C3 inhibitor, soluble complement receptor-
related protein y (sCrry), also caused a 2- to 3-fold increase in Aβ
deposition and increased neuropathology in APPmice [29]. A different
approach to complement modulation was used by Pillay and
colleagues [30] by employing Vaccinia virus complement control
protein (VCP), which inhibits both the classical and alternate
complement pathways. It improved memory performance in APP/
PS1 mice.
Although an activation of the complement system occurs in mouse
models of AD, several studies have pointed out signiﬁcant differences
between the human and mouse systems (for reviews see [31,32]). It
has been shown that mouse C1q binds to Aβ [23,26], but as Webster
and colleagues [33] demonstrated bindingwas less efﬁcient compared
to the human form, resulting in a lower activation of the mouse
complement complex in transgenic models compared with humans.
Immunostaining of plaque-associated complement proteins was
generally weaker in mice compared to AD [24](see Fig. 1). By using
erythrocyte lysis assays Ong et al. [34] showed that mice have lower
serum complement protein levels compared to humans and other
species. Ebanks and colleagues [35] found that mouse complement C4
lacked C5 convertase activity, preventing complement activation via
the classical pathway.
Taken together, these studies show that the complement system is
activated in transgenic models of AD (for summary see Table 1).
Complement protein expression is increased and associated with
plaques and glial cells. While C1q deﬁciency reduces neuronal
degeneration and improves learning, inhibition of the alternative
pathway (C3) increases Aβ pathology and neuronal loss. Important
differences between AD and mouse models are the lower expression
levels of the complement proteins, and possibly reduced binding of
C1q to Aβ as well as lack of late-stage complement activation [17].
These mouse models also fail to display extensive tau pathology and
widespread neuronal death. Tau aggregates are, in addition to Aβ
aggregates, possible activators of the complement system. Several
approaches of modulating the complement system in transgenic mice
have been shown to reduce neuropathology and/or Aβ load. It
remains to be determined if these interventions can also be effective
in human AD, particularly in early stages, before full-blown
complement activation exacerbates the severe degeneration in end
stage disease.2.2. Microglial activation in AD mouse models
There is a plethora of evidence that activated microglia contribute
to neurodegeneration in AD. Microglial cells are the immune effector
cells in the CNS and are part of the mononuclear phagocytic system,
expressing characteristic markers of phagocytes and immune cells,
such as complement components and their receptors, major
histocompatibility complex (MHC) glycoproteins, and scavenger
receptors (for review see [36,37]). Once activated, microglia
phagocytose targets, release cytokines and, if fully activated,
discharge toxic free radicals [38–40]. In neurodegenerative disorders,
such as AD, microglia fail to clear pathological protein aggregates
and cellular debris and become chronically activated, continuously
releasing neurotoxic substances and contributing to the pathogen-
esis [41]. It was long thought that microglia exist in either an
activated or a resting state. More recently it has been proposed that
microglia can be activated into either anti-inﬂammatory (alternative,
adaptive) or pro-inﬂammatory (classical, chronic) states, having
either beneﬁcial (Aβ clearance, release of neurotrophic factors) or
detrimental effects (release of pro-inﬂammatory cytokines, free
radicals) [7,42].
Fig. 1. Comparison of immunostaining and histology staining of the cortex of APP23 mice (A, C, E, G, I and K) and of a human AD case (B, D, F, H, K and L). (A) and (B) compare Aβ
deposits. (C) and (D) compare Bielschowsky histology staining demonstrating only few dystrophic neurites associated with Aβ plaques in APP23 mice but dense ﬁbrillary changes in
the AD case. (E) and (F) compare immunostaining for microglial cells. The mouse tissue is stained with an antibody against Iba1 and the human tissue with an antibody against HLA-
DR. (G) and (H) compare GFAP immunostaining for astrocytes (G is counterstained with Cresyl Violet, labeling all nuclei). (I) and (J) compare immunostaining of C1q of complement
(note that C1q association with plaques in tg strains has been reported by [23,25]), and (K) and (L) compare immunostaining for C3 of complement. Calibration bar: 50 μm.
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mouse models
In transgenic mouse models, activated microglial cells accumulate
in the vicinity of Aβ plaques, similarly to AD (Fig. 1). This has been
shown in various strains including Tg2576 (Swedish), APP 22
(Swedish/London), APP 23 (Swedish), and TgCRND8 (Indiana/
Swedish) [43–46]. While in other mouse models microglia are mainly
associated with compact (dense core) plaques [47], in TgCRND8mice,
which develop diffuse and compact plaques earlier than other strains
(at 9–10 weeks), microglia and astroglia were associated early on
with both types of plaques [46]. Early activation of microglia stained
with HLA-DR and CD11b was also reported in the PS19 model of
tauopathy which carry the human tau P301S mutation. Microglial
activation coincided with synaptic pathology, followed later by
ﬁbrillary tau pathology and astrogliosis [48]. Although Howlett and
colleagues [9,49] found no up-regulation of microglial CD11b in
TASTPM mice (double APP/PS1 transgenic), expression of Iba-1 was
greatly increased, suggesting a change in activation state.
Recent advances in imaging have made it possible to observe
individual cells in vivo over time. Using in vivo multiphoton
microscopy Meyer-Luehmann and colleagues [50] demonstrated
that plaques form within days in both Tg2576 and PS1/APP mice
and that microglial cells aggregate around these newly formed
plaques within 1 to 2 days, followed by dysmorphic changes toneurites. Despite the close association with microglia, the plaques
were not cleared, but possibly restricted from growing larger. In a
different in-vivo imaging study, it was observed that additional
microglial cells continue to migrate to plaques, that their volume
predicts changes in plaque size, and that the microglia closest to
plaques phagocytose more actively [51].
Microglia in SwDI mice were found to express complement
proteins C1q, C3, C4 [22]. Microglia expressing complement recep-
tor-3 (CR3, CD11) and astroglia were detected in APP/PS1 (Tg2576/
5.1PS1) transgenic mice as soon as the ﬁrst Aβ deposits formed at
6 months, but MHC-II expression was not found until 12 months of
age, coinciding with stabilization of ﬁbrillary Aβ and suggesting a
more severe state of inﬂammation and activation [52].
2.2.2. Modulation of states of microglial activity in transgenic mice
Several recent studies have focused on the regulation of microglial
activity via their receptors. CD40–CD40 ligand (CD40L) suppression
shifts microglia towards increased phagocytic activity (“anti-inﬂam-
matory state”). Tan and colleagues [53] crossed Tg2576 mice with
CD40L deﬁcient mice and reported decreased plaque loads and
microgliosis [54]. Interruption of CD40–CD40L interaction in vacci-
nated PSAPP and Tg2576 mice increased Aβ clearance via increasing
the phagocytotic activity of microglia, suggesting that CD40–CD40L
acts as a molecular switch between pro- and anti-inﬂammatory states
Table 1
Summary of studies on inﬂammation in mouse models of AD.
Model Experimental intervention Inﬂammatory response References
COMPLEMENT
SwDI UP mRNA C1q, C3; UP Western C1q, C3, C4; colocal.
complement w. ﬁb Aβ and microglia
[22]
PS/APP Colocal. C1q w. Aβ /MG [23]
Tg2576 UP C1q deposition w. age [25]
Tg2576 x C1q KO DN glia activation, DN neurodegeneration, unchanged plaque load [26]
Tg2576 x C1q KO DN C4, UP C3 [25]
APP22 x C3 KO UP plaque load, neuronal loss
MG express CD45
[28]
APP22 x sCrry TG UP Aβ deposition, UP neurodegeneration [29]
APP/PS1 Vaccinia virus complement control protein UP memory [30]
Tg2576, 3xTg-AD C5a receptor antagonist DN Aβ deposition, neurodegeneration, gliosis, phospho tau, UP behavior [27]
MICROGLIA
Tg2576 MG activation [43]
APP 22 MG activation [45]
APP 23 MG activation [44]
TgCRND8 Early MG association with diffuse and compact Aβ [46]
APP/PS1 UP Iba-1, unchanged CD11b in MG [9,49]
PS19 (tau) MG activation [48]
APP/PS1 and Tg2576 MG aggregate near plaques and phagocytose [50,51]
SwDI MG express C1q, C3, C4 [22]
APP/PS1 MG express CR3 (CD11) at 6 mo and MHC-II at 12 mo [52]
Tg2576 x CD40L deﬁcient strain DN microgliosis and Aβ load [53,54]
PSAPP, Tg2576 x CD40 or neutralizing CD40L antibody, Active Vacc. Up Aβ clearance, UP MG phagocytosis [55]
PSAPP and Tg2576 infusion with human umbilical cord blood cells UP MG phagocytosis via suppression of CD40–CD40L interaction [56]
Tg2576 x CD40L/CD40 KO DN tau phosphorylation [57]
Tg2576 x CCR2 KO DN MG recruitment to plaques, UP Aβ aggregation, memory impairment [58]
APP/PS1 x TLR2 KO DN MG recruitment to plaques, UP Aβ aggregation, memory impairment [59]
APP/PS1 x LXR KO UP Aβ load [60]
Tg2576 LXR agonist DN Aβ deposits, DN CD45+ MG, DN IL-6 mRNA [61]
APP/PS1 M-CFS UP number of MG, UP Aβ phagocytosis, DN Aβ deposits [62]
Tg2576 Exercise DN IL-1β Aβ, TNF-α, UP MHC-II [63]
Tg2576 x C1q KO DN MG activation, unchanged plaque load [26], [25]
APP x C3 KO UP MG CD45, DN MG F4/80 and CD68 [28]
APP/PS1 Glatimer acetate vaccination UP MG CD11c, UP IGF, Aβ clearance [65]
Tg2576 LPS, intracerebral
Dexamethasone
UP MG activation, UP Aβ clearance
Blocks activation
[66]
SwDI Minocycline DN MHC-II MG, DN IL-6, UP memory, no change to Aβ deposition [67]
APPswe Aged mice
UP Aβ
UP MG expression of pro-inﬂammatory genes [68]
APP/PS1 Aged mice
UP Aβ
UP MG TNF-α, iNOS [69]
APP/PS1 Pass. Vaccine Activation CD45+ MG, clearance of Aβ [83]
PDAPP Pass. Vaccine MG migrate to plaques [85]
APP23, Tg2576 DNA vaccines UP phagocytosis, number of MG, DN Aβ burden [88,89]
APP/PS1 Pass. Vaccine UP number of MG, but no change in Aβ clearance [90]
CYTOKINES
Tg2576 UP IFN-γ; IL-12 and IL-4 absent [96]
Tg2576 UP IL-1β, TGF- β, IL-10, IL-6 [95]
Tg2576 UP IL-1 β, TGF- β, IL-6 [94]
Tg2576, PS1/APPsw UP TNF-α, IL-6, IL-12p40, IL-1 β, IL-1 α, GM-CSF [97]
3xTg-AD UP TNF-α, MCP-1 [98]
3xTg-AD dominant negative TNF inhibitor DN Aβ deposition [99]
APP23 x TNF-αR KO DN Aβ deposition, neuronal loss [100]
Tg2576 Exercise DN TNF- α, IL-1 β, Aβ
UP IFN-γ, MIP-1 α, CD40, MHC-II, CD11c
[63]
Tg2576 x IFN-γ R 1 KO DN TNF-α, BACE1, Aβ plaques [101]
APPswe x TLR-4 KO DN TNF-α, IL-1β, IL-10 and IL-17 [102]
APPswe/PS1 UP IL-1β DN Aβ [103]
hAPP x TGF-β1 (AG) DN Aβ [104]
TGF-β1 UP Aβ (murine) [105]
Tg2576 x CCL2 (MCP-1) UP glial activation, Aβ deposition [107]
APP/PS1 AAV-dominant-negative CCL2 DN glial activation, Aβ deposition [107]
AG: astroglia; DN: downregulation, reduction; MG: microglia; MIP: macrophage inﬂammatory protein; PassVaccine: passive vaccination; UP: upregulation, increase, improvement;
x crossbreeding.
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also shown in Tg2576 and PSAPP mice after infusion with human
umbilical cord blood cells, via suppression of CD40–CD40L interaction
[56]. CD40L or CD40 deﬁciency also reduced pathological tau
phosphorylation in Tg2576 mice [57].
Impairment of microglia recruitment to plaques by inducing a
deﬁciency of CCR2, a microglial chemokine receptor [58], or the innateimmune receptor toll-like receptor 2 (TLR2, [59]) increased Aβ
aggregation and accelerated memory impairment, indicating that
microglial chemotaxis is important in controlling Aβ deposition.
Liver x receptor (LXR) plays a dual role in controlling
cholesterol homeostasis, while inhibiting inﬂammation. Loss of
LXR in APP/PS1 mice leads to increased plaque load. In cell culture,
LXR activation reduced the microglial inﬂammatory response to
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of Tg2576 mice with the LXR agonist GW3965, reduced Aβ
deposits by half, and was accompanied by reduction in the number
of CD45+ microglia as well as interleukin (IL)-6 mRNA expression
[61]. The authors suggest that LXR acts via increased expression of
lipidated ApoE.
Microglial activity can also be altered by modiﬁcation of cytokine
levels. Treatment of APP/PS1 mice with macrophage colony-
stimulating factor (M-CSF) increased the number of microglial cells,
as well as their phagocytosis of Aβ and reduced the number of Aβ
deposits [62]. Nichol and colleagues [63] found that exercise induced a
shift from pro-inﬂammatory to anti-inﬂammatory microglial activa-
tion in Tg2576 mice. Exercise resulted in reduced expression of the
pro-inﬂammatory cytokines IL-1β and tumor necrosis factor (TNF)-α,
increased MHC-II levels (indicating a shift to an antigen-presenting
state), and induced a trend towards reduction in levels of aggregated
Aβ.
As reviewed earlier in this article, there is good evidence for an
activation of the complement system in ADmousemodels. Alterations
in the level of complement components also modulate microglial
activation. Microglial accumulation, C4 levels and neurodegeneration
were reduced in C1q deﬁcient Tg2576 and APP/PS1 mice, while C3
levels were increased and Aβ load remained unchanged [25,26].
Extrinsic C1q can shift microglia into a pro-inﬂammatory activation
state, as demonstrated recently in wildtype rat cell culture [64]. In a
different set of experiments Maier et al. [28] showed that reducing
levels of C3 led to increased microglia/macrophage CD45 levels while
F4/80 and CD68 showed a trend toward reduction, suggesting a
switch in phenotype of microglia.
Butovsky and colleagues [65] showed that T-cell-based immuni-
zation of APP/PS1 mice with glatimer acetate caused a phenotype
switch in microglia inducing CD11c and insulin-like growth factor 1
expression as well as increased clearance of Aβ. This was also
accompanied by increased neurogenesis.
Intracerebral injections of lipopolysaccharide (LPS) induced
neuroinﬂammation associated with clearance of Aβ and microglial
activation. Dexamethasone inhibited microglial activation and Aβ
clearance [66].
Minocycline is a tetracycline with anti-inﬂammatory properties
and reduces microglial activation. Although minocycline treatment
did not alter Aβ deposition in SwDI mice, it reduced the number of
MHC-II microglia and IL-6 expression as well as improving learning
performance [67]. The studies of minocycline treatment and C1q
deﬁciency show that the harmful effects of microglia can be
ameliorated in mouse models independently of Aβ levels.
Aβ itself can inﬂuence the balance between pro- and anti-
inﬂammatory activation. It drivesmicroglia towards apro-inﬂammatory
state. While microglia of wild-type mice subjected to traumatic
brain injury predominantly produce anti-inﬂammatory factors,
microglia in APPswe mice have increased expression of pro-
inﬂammatory genes [68]. Jimenez and colleagues [69] reported that
in 6-month-old APP/PS1 mice, microglia are TNF-α negative and
phagocytose Aβ in accordance with an anti-inﬂammatory pheno-
type, while microglia of 18-month-old mice have switched to a pro-
inﬂammatory phenotype with increased TNF-α and inducible nitric
oxide synthase (iNOS) expression. The authors suggest that soluble
oligomeric Aβ, which had increased 10-fold by 18 months, may be
responsible for this switch. This phenotypic switch may be the
murine equivalent of “microglial senescence”, leading to deﬁciency
in phagocytosis and immune defense in aged human brains [70] or
“inﬂammaging” [71], a chronic up-regulation of the pro-inﬂamma-
tory state associated with aging.
2.2.3. Resident brain microglia vs. peripheral, bone-marrow derived cells
An interesting question is whether inﬁltrating peripheral macro-
phages enter the brain and whether they take part in clearance of Aβ.It has been shown that in whole-body irradiated mice, peripheral
macrophages cross the blood-brain barrier and differentiate into
CD11c positive microglia. Such inﬁltrated cells are more efﬁcient as
phagocytes than the resident cells [72,73]. Considerable inﬁltration of
peripheral macrophages and accumulation near vessels and plaques
was induced when transforming growth factor (TGF)-β-Smad2/3
signaling was interrupted in immune cells of Tg2576 mice, accompa-
nied with a substantial reduction of Aβ deposits and improved
learning [74]. The potential of bone-marrow derived cells for Aβ
clearance was also demonstrated by Butovsky and colleagues [75],
who speciﬁcally ablated these cells by irradiation in APP/PS1 chimeric
mice. The number of CD11c+ cells in brain was reduced and Aβ
deposition increased. It is still a point of debate as to whether
peripheral recruitment can occur without damage of the blood-brain-
barrier, since much of the data are derived from experiments using
whole-body irradiation [72,75]. A different approach was used by
Ajami and colleagues [76] who created parabiotic mice with
peripheral blood chimerism in which one of the chimeric partners
expressed GFP in hematopoietic cells. Whenmicrogliosis was induced
in the GFP-negative partner, none of the microglial cells was GFP-
positive, suggesting that the microgliosis resulted from expansion of
the local brain microglial pool.
2.2.4. Microglia are involved in vaccination-mediated clearance of Aβ
Both active and passive Aβ based vaccination protocols have been
used successfully in ADmousemodels to reduce the Aβ burden and to
improve behavioral functions (for reviews see [77–79]). Encouraged
by such positive results, a clinical trial in human patientswas initiated,
but was hampered by unwanted side effects, such as meningoen-
cephalitis, stroke and even death [80,81]. Subsequent clinical trials are
aimed at avoidance of inﬂammation, complement activation and
inappropriate T-cell responses.
Several distinct mechanisms for vaccination results have been
proposed but we include only studies with relevance to microglial
activation and phagocytosis in this review.
It has been proposed that one of the effects of Aβ vaccination is a
shift in the state of microglia towards a phenotype with increased
phagocytotic activity and limited production of inﬂammatory
cytokines [82]. Wilcock and colleagues [83] reported activation
of CD45+ microglia after intracranial injection of anti-Aβ
antibodies. Anti-inﬂammatory drugs reduced microglial activation
and inhibited ﬁbrillary Aβ clearance. This suggests that microglial
activation is necessary for clearance of compact deposits. The
same authors showed also that microglial activation (upregulated
CD45) was transient after repeated vaccination of APP/PS1 mice
with Aβ [84].
Using in vivo two-photonmicroscopy imaging in PDAPPmice with
GFP labeled microglia, Koenigsknecht-Talboo and colleagues [85]
showed that microglia migrate to Aβ plaques within 3 days after
systemic administration of an anti-Aβ antibody (m3D6). Microglia did
not react to a different antibody which recognizes only soluble Aβ
(mHJ5) or to Fab fragments of m3D6. This indicates that antibodies
against different Aβ epitopes have differing effects on microglia
activation. Similar effects were also shown by Bard et al. and Gray et
al. [86,87] who found that antibodies against the Aβ N-terminus
activated phagocytosis, while C-terminal antibodies acted by periph-
eral sequestration of Aβ.
Aβ DNA vaccines were used as an alternate approach for
immunotherapy and they have been shown to work effectively in
mouse models. Okura and colleagues [88] reported that increased
phagocytotic activity and numbers of microglia were the main
drivers of Aβ clearance in their model (APP23), while inﬂammatory
cytokine TNF-α expression remained unchanged. Mouri and cow-
orkers [89] used Aβ cDNA in an oral vaccination paradigm in Tg2576
mice and reported reduction in Aβ burden without lymphocytic
inﬁltration.
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in vaccination-induced Aβ clearance, others suggest that microglia
have only a limited role [90]. The number of microglial cells associated
with plaques signiﬁcantly increased when the anti-Aβ antibody 10D5
was directly applied into the brain of APP/PS1 mice and was further
increased by IFN-γ. Inhibition of microglia with anti-Mac1-saporin or
minocycline reduced the number of microglia. Effects of microglial
inhibition or activation on Aβ clearance, in addition to 10D5 effects,
were limited.
In summary (see also Table 1), these studies demonstrate that in
transgenic AD mouse models, microglia are activated, accumulate
around Aβ deposits, and are involved in their clearance (although one
study only shows a limited role [90]). It will be very interesting to see
if further studies on modulating microglial activity towards alternate,
anti-inﬂammatory states can lead to an improved clearance of plaques
and/or reduced neurodegeneration. It will also be important to search
for possible differences between mouse and human microglial
activation, such as NOS production and microglial senescence. In
contrast to human microglia which do not produce measurable
amounts of NOS, murine microglia produce large quantities when
subjected to the same type of stimulation [91].
2.3. Cytokines in AD mouse models
Up- or down-regulation of the expression of various pro- and anti-
inﬂammatory cytokines has been widely reported in AD patients (for
reviews see: [7,92,93]). Similar changes in cytokine expression have
been shown in transgenic mouse models of AD. The cytokines IFN-γ,
IL-12, TNF-α, IL-6, IL-1β, IL-1α, TGF-β, and IL-10, monocyte
chemoattractant protein (MCP)-1 and granulocyte-macrophage
(GM)-CSF were reported to be up-regulated in various transgenic
mouse models (Tg2576, TgAPPsw, PS1/APPsw, 3xTg-AD), while IL-4
was found to be down-regulated [94–98].
In addition, experimental manipulation of the cytokine system has
been shown to affect the AD type pathology in these models.
Disruption of the soluble TNF-α signaling with dominant negative
TNF inhibitors (DN-TNFs) in the 3xTg-AD (APP/PS1/tau) model
prevents intraneuronal Aβ accumulation [99]. Deletion of the TNF-α
receptor TNFR1 in APP23 mice resulted in reduced plaque formation
and limited neuronal loss [100]. Exercise was shown to reduce TNF-α
and IL-1β in Tg2576 mice to wild-type levels, accompanied by an
increase in IFN-γ, macrophage inﬂammatory protein (MIP)-1α, CD40,
MHC-II, CD11c and reduced Aβ levels [63].
Suppression of IFN-γ signaling in Tg2576mice via IFN-γ receptor 1
knockout reduced Aβ plaque load and gliosis [101]. The same authors
showed that in glial cell cultures TNF-α and BACE1 expression was
reduced in mutants, suggesting that this pathway is involved in Aβ
formation. Microglial production of TNF-α, IL-1β, IL-10 and IL-17 is
up-regulated in APPswe mice, but this up-regulation was blocked by
knock-out of the TLR-4 gene [102]. Shaftel and colleagues [103]
demonstrated that in APPswe/PS1 mice, local overexpression of IL-1β
resulted in an inﬂammatory response and led to a reduction in Aβ
deposition, possibly through enhanced microglial Aβ degradation. A
moderate increase in astroglial TGF-β1 expression resulted in a
reduction of Aβ deposition in hAPP mice (K670M/N671L and V717F)
[104]. These ﬁndings seem inconsistent with the reported increased
Aβ production in TGF-β1 transgenic mice (not transgenic for APP)
[105]. Over-expression of CCL2 (MCP-1) in double transgenic Tg2576
mice increased glial activation and Aβ deposition [106], while gene
delivery of a dominant-negative CCL2 mutant reduced gliosis and Aβ
deposition in APP/PS1 mice [107].
In summary, inﬂammatory cytokines levels in transgenic mouse
models reﬂect similar changes in AD. Their modulation regulates
microglia activity in these models. These studies are summarized in
Table 1. It will be interesting to see if this can be translated into a
useful therapeutic strategy in humans.2.4. Efﬁciency of NSAIDs in AD mouse models
Evidence of chronic inﬂammation in the brain of AD patients,
including upregulation of inﬂammatory cytokines, over-activation of
microglia, and neurotoxic effects from the activated glia, suggests that
NSAIDs may be useful in the treatment and prevention of AD. In
addition to the pathological evidence for activation of the immune
system, the majority of epidemiological studies have demonstrated
that long-term exposure to certain NSAIDs reduces the risk of AD in
humans. The large Rotterdam study demonstrated that long-term use
of ibuprofen (2 years and longer) reduced the relative risk of
developing AD to 0.2 (95% CI 0.05–0.83) [108]. Incidence of AD was
also reduced in users of NSAIDs (ibuprofen, naproxen and indometh-
acin) in the Baltimore longitudinal study of aging [109]. These and
other epidemiological studies are reviewed in [110]. Although some
newer studies found no beneﬁts of NSAIDs, another recent study using
records of the Veterans Affairs Health Care System showed that long-
term NSAID use protected against AD [111].
With such epidemiological rationale, several trials in transgenic
mouse models of AD have been conducted to assess the effectiveness
of NSAIDs. Ibuprofen, the most commonly used NSAID in humans,
was successfully utilized in the majority of transgenic studies.
Feeding 10-month-old Tg2576 mice with chow mixed with
ibuprofen for 6 months reduced the number and area of Aβ plaques,
as well as IL-1β and glial ﬁbrillary acidic protein levels [112]. Yan et
al. [113] reported a similar reduction of plaque load (60%) in Tg2576
when ibuprofen treatment was started at 11 months of age. But they
found no effect of pioglitazone (a peroxisome proliferator-activated
receptors (PPAR) γ agonist). In double-transgenic mice (APP/PS1),
which develop plaques at an earlier age, Jantzen et al. [114] found
that a nitric oxide-releasing derivative of ﬂurbiprofen (NCX-2216)
reduced the Aβ load dramatically, accompanied by an increase in the
number of MHC-II expressing microglia. Ibuprofen reduced the Aβ
load moderately, and celecoxib (a cyclooxygenase (COX)-2-selective
NSAID) had no effect. A different nitric oxide-releasing derivative of
ﬂurbiprofen (HCT 1026) also reduced the Aβ load and microglial
activation near plaques [115].
R-ﬂurbiprofen, which is not a COX inhibitor, was found to be
effective in improving spatial learning deﬁcits in Tg2576 if
administered to younger mice [116]. If the drug was used after
plaque development ensued, the plaque load was reduced but the
learning deﬁcit was not ameliorated. When treating 10-month-old
APP V171I transgenic mice with pioglitazone (at a higher dose than
[113]) and ibuprofen for only 7 days, Heneka et al. [117] found a
reduced number of activated microglia and reactive astrocytes,
decreased expression of COX-2, iNOS and BACE1, and reduction of
Aβ deposits and soluble Aβ42. Also, in the Tg2576 mouse model,
Morihara et al.[118] reported that ibuprofen reduced IL-1β and the
pro-amyloidogenic α1-antichymotrypsin (ACT) expression. They
suggested that ibuprofen reduced the Aβ burden via this pathway.
In a recent study on triple transgenic mice (APPswe, PS1M146V,
tauP301L), ibuprofen reduced intraneuronal oligomeric Aβ, cognitive
deﬁcits, and hyperphosphorylated tau immunoreactivity [119]. But
when ibuprofen was given to 3-month-old Tg2576 mice for a very
short duration (4 days), no effect on Aβ levels was observed [120].
Indomethacin and a lecithin derivative (DP-155) were shown to be
effective in reducing Aβ levels in Tg2576 mice [121–123]. Drugs
which inhibit COX-2 did not reduce Aβ burden or even increased Aβ
levels in mouse models [114,122,124].
The proposed mechanisms of action for NSAIDs include reduction
of inﬂammation via COX inhibition [125,126] or inhibition of
cytokine expression (IL-1β, α1-ACT, [118]). In addition, certain
NSAIDs have been shown at high concentration to reduce Aβ
production by modulation of γ-secretase activity [127]. Some also
act as agonists of PPARγ and by modulation of Rho-GTPase (reviewed
in [128]).
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NSAIDs in transgenic mice, the outcomes of clinical trials in humans
have been disappointing and have, in some cases, been accompanied
by cardiovascular or gastrointestinal side effects. Several COX-2-
selective NSAIDs (Nimesulide, Celecoxib, Rofecoxib) and non-
selective NSAIDs (indomethacin, diclofenac, naproxen, ibuprofen)
have been used in trials, but beneﬁts were either very small or
absent (for review see [110,128]).
3. Transgenic mouse models of Parkinson's disease
The 1988 report describing reactive microglia within the sub-
stantia nigra of PD patients was the ﬁrst line of evidence to support
the involvement of the immune system in PD [129]. Since then there
have been numerous studies showing that inﬂammatory processes
play an important role in the pathogenesis of PD, and several recent
reviews have summarized the current state of our understanding of
neuroinﬂammatory processes in PD [4,130–132]. Similarly to AD, the
evidence stems from observations in human postmortem tissue of
reactive microglia and astrocytes in the affected areas. Such ﬁndings
were supported by genetic studies identifying correlations between
polymorphisms of genes associated with inﬂammatory responses and
the risk of PD. They were further supported by epidemiological data
showing protective effects of chronic use of anti-inﬂammatory drugs
and by functional animal studies showing that activation of the
inﬂammatory response in the central nervous system may lead to
selective loss of dopaminergic neurons and that anti-inﬂammatory
treatments ameliorate neuronal and behavioural deﬁcits observed in
these animals.
Additional support for the inﬂammatory hypothesis in the case of
PD comes from the investigation of an accidental human model of the
disease. In 1983 Langston et al. [133] reported that drug addicts who
consumed a synthetic product containing the previously undiscov-
ered neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) developed symptoms that were very similar to idiopathic
PD. A dissimilarity was noted in the pathological examination at
autopsy since these patients did not develop Lewy bodies. Neverthe-
less, therewas a selective loss of dopaminergic neurons and continued
presence of activated microglia. In one case, this sign of inﬂammation
was seen as late as 16 years after the exposure to the agent [134].
These observations were supported by later studies on MPTP-treated
monkeys that showed both microglial and astroglial reactions up to
14 years after the experimental treatment [135,136]. The presence of
reactive immune cells years after the initial toxic insult indicates that
inﬂammatory processes in these cases, and possibly also in idiopathic
PD, may evolve into self-sustaining mechanisms that are damaging to
selective groups of neurons. A number of functional animal models of
PD that use various toxins (e.g. 6-OH-dopamine, MPTP, rotenone) or
exogenous immune mediators (e.g. LPS) have demonstrated robust
activation of neuroimmune mechanisms that are accompanied by
neuronal death in the substantia nigra. Furthermore, several of these
models rely on immune activation of glial cells as the trigger of
selective loss of dopaminergic neurons (reviewed in [41,131,137]). In
transgenic animal models of PD, the identiﬁcation of inﬂammatory
mechanisms has proven to be more challenging. In similarity to AD,
transgenic animal models of PD have been created based on
knowledge of gene mutations associated with the human disease.
They include α-synuclein (Asyn), DJ-1, LRRK2, Parkin, PINK1 and
UCH-L1 [138–141]. Thus far transgenic PD models have been created
in three different species: mice, as well as Drosophila melanogaster
and Caenorhabditis elegans. Only in the latter two species has the
incorporation of Asyn mutations resulted in a consistent loss of
dopaminergic neurons. This illustrates that genetic manipulation
alone may not be sufﬁcient to trigger the pathogenesis of PD and that
additional environmental factors are needed [137]. Even though the
genetically modiﬁed animals display certain pathophysiological andbehavioural characteristics of PD, there have been very few reports
describing neuroimmune responses associated with the genetic
manipulations. A scarcity of pertinent information does not rule out
the possibility that immune responses are evoked by genetic
manipulations. Future experiments in transgenic animals may
establish such correlations. Below we review the evidence obtained
thus far from the various groups of transgenic animal models of PD.
3.1. Alpha-synuclein transgenic mouse models
This is the most studied group of animals, perhaps due to the fact
that alpha-synuclein (Asyn, PARK 1) was the ﬁrst gene to be linked to
PD. Asyn has also become the most studied PD-associated protein.
Three different mutations (A30P, A53T and E46K) as well as genomic
duplication and triplication of a locus containing the Asyn gene have
been linked to familial forms of PD [142–145]. The ﬁrst Asyn
transgenic mice were created by Masliah and colleagues [146] by
expressing wild-type human Asyn in neuronal cells under the
regulatory control of the platelet-derived growth factor-b (PDGF-b)
promoter. This resulted in progressive accumulation of Asyn and
ubiquitin-immunoreactive inclusions in neurons in the neocortex,
hippocampus and substantia nigra. Although loss of dopaminergic
terminals in the basal ganglia and motor impairments were observed,
there was no substantial decrease in the number of dopaminergic
neurons and no glial activation was reported [146]. Since then, pan-
neuronal expression of Asyn has been achieved by using PDGF-b, Thy1
or prion protein promoters. In contrast the tyrosine hydroxylase (TH)
promoter has been used to restrict Asyn expression to catecholamin-
ergic neurons.
Even though some of the transgenic models mimic certain stages
or features of human PD, none of them display the full pathological
cascade of PD (reviewed in [147,148]). While neurodegeneration is
absent in some cases, it is non-speciﬁc or of late onset in others.
Similarly, the evidence of immune system involvement has not been
consistent and depends on the type of Asyn and the promoter used.
Thy1 is another promoter that has been used in addition to PDGF-b
to achieve broad expression of Asyn in mouse neurons. The Thy1
transgenic mouse lines have a wide range of phenotypes with
different patterns of Asyn expression [147]. Activated microglia
associated with Asyn inclusions have been observed in these mice
[138]. However this upregulation was not conﬁrmed in the samemice
after paraquat injection, which may have been due to the fact that
microglial activation occurs concomitant to neuronal death and is not
detectable 2 weeks after the onset of neuronal degeneration [149].
Lewy-like pathological changes in neurons were reported in mice
expressing the Thy1-driven A53T mutant form of human Asyn.
Astrocytic gliosis and microglial activation accompanied motor
neuron pathology, which was also seen in other affected brain regions
[150].
Giasson and colleagues [151] reported that pan-neuronal over-
expression of A53T Asyn leads to signiﬁcant astrogliosis in the spinal
cord, which was interpreted as being consistent with neuronal injury.
These mice displayed motor impairments although no signiﬁcant loss
of motor neurons was observed. A more severe phenotype of A53T
Asyn mice was described by Lee et al. [152] who reported adult-onset
neurodegeneration leading to progressive motor dysfunction and
eventual death of the animals. A prominent astroglial reaction was
observed in areas affected by neurodegenerative changes. Interest-
ingly, mice expressing the wild-type or A30P variant of Asyn did not
develop such pathology [152]. The above two studies used the mouse
prion protein promoter which generally leads to high levels of Asyn
protein expression. Despite this fact, not all mice expressing A53T,
even under the control of the prion promoter, displayed a glial
reaction. Negative results have also been reported [153].
High levels of A30P Asyn expression in the Tg5093 mouse line was
associated with a progressive motor disorder characterized by
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mice did not exhibit speciﬁc deterioration of the nigrostriatal
dopaminergic neurons, they did display neuropathological features
including age-related central nervous system astrocytosis and micro-
gliosis. Gliosis was evident in the hippocampal formation at the age of
7–8 months in heterozygote mice and at 4 months in the homozygote
mice [154].
In a more recent study, Su et al. [155] characterized inﬂammatory
responses in mice expressing human wild-type Asyn under control of
the rat TH promoter. Asyn expressing (SynWT+/+) animals
exhibited a signiﬁcant increase in the number of activated microglia
in the substantia nigra at 1 month compared to age-matched control
animals. They also had signiﬁcantly higher levels of expression of the
pro-inﬂammatory cytokine tumor necrosis factor (TNF)-α. Similarly,
expression of truncated human Asyn(1–120), driven by the rat TH
promoter, led to the formation of pathological inclusions in the
substantia nigra; even though no signiﬁcant cell loss was observed, an
increase in microglial cells was evident [156]. A lack of microgliosis
has also been reported in mice expressing a truncated (1-130) form of
Asyn with the A53T mutation [157].
Transgenic mice with oligodendrocyte-speciﬁc expression of wild-
type Asyn were created to model multiple system atrophy (MSA)
since Asyn-positive glial inclusions are a major histopathological
hallmark of idiopathic MSA [158]. These mice showed early and
progressive microglial activation in the substantia nigra pars
compacta (SNc), which was associated with increased expression of
iNOS and loss of dopaminergic neurons. Suppression of microglial
activation by minocycline protected dopaminergic SNc neurons [158].
Transgenic mice overexpressing human Asyn have also been used to
perform functional animal experiments by using various toxins and
immune mediators to trigger neurodegeneration. For example, Gao et
al. [159] studied the effects of bacterial LPS injection in mice that
expressed human wild-type or mutant A53T Asyn in the absence of
murine Asyn (Asyn-null background). Stereotaxic injection of LPS into
the substantia nigra caused a similar inﬂammatory reaction in all
animals studied. However, loss of dopaminergic neurons and
aggregates of Asyn were observed in mice overexpressing wild-type
and mutant Asyn but not in Asyn-null control mice. Furthermore, ex
vivo glial cultures or mixed neuron/glial cultures from transgenic
animals overexpressing or lacking Asyn have been used to demon-
strate differences in microglial phenotype and their ability to produce
pro-inﬂammatory and toxic species [159,160]. Thus microglia from
Asyn knock-out animals displayed a reactive phenotype and increased
cytokine secretion, but impaired phagocytic ability [160]. This
indicates that Asyn plays a major role in regulating the microglial
activation state. Human Asyn overexpressing mice were also used to
study the effects of immunization with Asyn. Since immunization has
been shown to reduce the amyloid burden and reduce the pathology
in a number of AD transgenic mouse lines, Masliah et al. [161]
vaccinated human Asyn overexpressing transgenic mice with human
Asyn. In mice that produced high afﬁnity antibodies against Asyn
there was a decreased accumulation of Asyn aggregates and reduced
neurodegeneration. Even though vaccination did not induce a
signiﬁcant glial reaction, these experiments clearly demonstrate
involvement of the immune system in regulating Asyn aggregation
and its associated neurodegenerative pathology.
In summary, due to the various Asyn forms, as well as different
promoters and strains of animal used, there have been signiﬁcant
inconsistencies between various studies. It appears that glial reactions
typically accompany neuronal cell death, if and when it occurs.
However, several reports have described glial activation in the
absence of signiﬁcant neuronal death, which may indicate that Asyn
is a signaling molecule released not only from dying neurons, but also
from neurons that are functionally compromised or are just simply
overexpressing Asyn. Support for this hypothesis comes from a study
demonstrating that neurons overexpressing Asyn secrete highconcentrations of Asyn which are capable of activating microglia
[155], and from in vitro observations that extracellular Asyn can be
recycled by neurons and is an effective pro-inﬂammatory stimulant of
both microglia and astrocytes [162–166]. Alternatively, the formation
of neuronal inclusions, the development of neuronal deﬁcits, and
neuroimmune responses, may not be linked in a causal chain.
3.2. DJ-1, Parkin and PINK transgenic mouse models
Mutations in DJ-1, PARK and PINK genes produce rare inherited
forms of PD. DJ-1 at the PARK7 locus has been linked to multiple
cellular processes including oxidative stress responses. At least three
different lines of DJ-1 knockout mice have been created, which show
decreased motor functions without clear loss of dopaminergic
neurons [139,167–169]. None of these studies reported inﬂammatory
responses in DJ-1 knockout mice.
PINK1 (PARK6) is believed to play an important role in
mitochondrial function, while Parkin (PARK2) is important in protein
targeting for proteosomal degradation. PINK1-defﬁcient and Parkin
(PARK2) knockout mice do not exhibit loss of dopaminergic neurons
and alterations in inﬂammatory markers have not been reported
[139,170–178]. Recently, Frank-Cannon et al. [170] reported that
long-term intraperitoneal administration of LPS induced neuroin-
ﬂammation, whichwas accompanied by ﬁnemotor deﬁcits and loss of
dopaminergic neurons in Parkin-deﬁcient (parkin−/−) mice, but not
in wild-type animals. Meanwhile Thomas et al. [179] reported that
nigrostriatal dopaminergic neurons in Parkin knockout mice did not
show increased susceptibility to the parkinsonian neurotoxin, MPTP,
which was administered in various doses.
There are a number of other transgenic mouse models that
resemble human PD that still have not been characterized with regard
to immune system involvement. One example are MitoPark mice,
which were created by conditional knockout of the gene for
mitochondrial transcription factor A (Tfam) in dopaminergic neurons.
These mice have reduced mitochondrial DNA (mtDNA) expression
and respiratory chain deﬁciency in midbrain DA neurons. This leads to
adult onset formation of intraneuronal Asyn negative inclusions,
dopaminergic cell death, and associated progressive impairment of
motor function [180].
Other transgenic mouse models involve genes that do not have
identiﬁed mutations associated with PD, but which nevertheless may
be involved in the pathogenesis of this disease. Thus, the naturally
occurring murine weaver mutant (gene symbol, wv) carries a
mutation in the gene encoding the G-protein which inwardly rectiﬁes
the potassium channel Girk2. It has been reported that in these mice
the degeneration of midbrain dopaminergic neurons, unlike other
types of neurons, is mediated via neuroinﬂammatory mechanisms
[181].
Mallajosyula et al. [182] reported the creation of inducible
monoamine oxidase B (MAO-B) transgenic mice. Astrocytic MAO-B
levels were speciﬁcally induced in adult animals, which caused
selective and progressive loss of dopaminergic neurons in the
substantia nigra. Since local microglial activation was observedwithin
the substantia nigra in addition to global astrogliosis, these mice may
provide a new model for the investigation of the neuroinﬂammatory
features of PD.
Transgenic mice deﬁcient in various key signaling molecules have
been widely used to investigate the role of speciﬁc molecular
pathways in neuroinﬂammatory processes associated with PD
pathology. Examples include mice deﬁcient in MAPK-activated
protein kinase 2 (MK2) [183], complement C3 [184], protease-
activated receptor 1 (PAR1) [185], IL-1α/β [186], MCP-1/CC chemo-
kine ligand 2 (Mcp-1/Ccl2) [187], (TNF)-α receptors R1 and R2 [188]
and prostaglandin E2 receptor subtype 2 (EP2) [189].
Transgenic models of PD have also been created by using
invertebrates, namely C. elegans and Drosophila. While these species
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which allows for the study of this protein in naïve organisms [190],
the obvious disadvantage in using any ﬂy or worm model is the
potential risk that a critical factor in the pathology of the diseases is
speciﬁc to mammals in general or humans in particular [191].
Immune reactions may be an example of a mammal-speciﬁc
mechanism, which could explain why we were unable to identify
any publications describing glial or other immune activation in the
two invertebrate models of PD.
4. Transgenic mouse models of Huntington's disease
Huntington's disease is a hereditary polyglutamine disorder
caused by extension of the triplet repeat region of the huntingtin
(htt) gene. HD is characterized by severe atrophy of the striatum,
where up to 95% of the medium spiny neurons degenerate, as well as
by the presence of intracellular and intranuclear htt inclusions, and by
reactive gliosis.
Evidence for involvement of inﬂammation in the pathogenesis of
HD includes reports on activation of the complement system,
increased microglial activity and up-regulation of inﬂammatory
cytokines. Singhrao and colleagues [192] found complement activa-
tion and increased mRNA levels for complement proteins and
regulators (C1q C chain, C1r, C4, C3, C1 inhibitor, clusterin, membrane
cofactor protein, decay accelerating factor, CD59) in HD brain tissue.
Increased protein expression of complement components C7 and C9,
complement inhibitor clusterin and acute phase protein α-2-
macroglobulin was shown in HD plasma and cerebrospinal ﬂuid
[193]. Activated microglia expressing HLA-DR were reported in
affected areas in HD [194]. These microglial cells were found in
close association with degenerating neurons [195]. The peripheral
benzodiazepine receptor is selectively expressed by brain microglia.
Increased binding of its ligand PK11195 has been described in
postmortem HD putamen and frontal cortex [196]. Using PK11195
for positron emission tomography (PET) imaging, increased micro-
glial activation was demonstrated in HD patients and in presymp-Fig. 2. Possible mechanism of inﬂammatory response in mouse models of Atomatic carriers of the mutated htt gene, indicating that microglial
activation is an early event in HD pathogenesis [197,198]. Microglial
activation correlated inversely with raclopride binding, a marker of
striatal cell function [199].
Data on microglial activation in HD mouse models are relatively
sparse. In both HD patients and R6/2 mice, expression of ferritin in
microglia is increased and the microglial cells appear dystrophic
[200]. But unlike the human HD cases, microglial size and density is
reduced with age in R6/2 mice [201].
Upregulation of inﬂammatory and anti-inﬂammatory cytokines
has been reported in the plasma (IL-6, IL-8, IL-4, IL-10, TNF-α) and
striatum (IL-6, IL-8 and TNF-α) of HD patients [193,202]. Interest-
ingly, IL-6 plasma levels were found to be increased in presymptom-
atic HD mutation carriers 16 years prior to the predicted onset of the
disease, suggesting that inﬂammatory changes commence very early
in the disease process [202]. HD monocytes showed increased IL-6
expression when activated by LPS and IFN-γ. R6/2 microglia and
YAC128 macrophages were similarly hyperactivated and protein
expression of IL-6, IL-10, IL-1β or IL-12p70was increased in R6/2, Hdh
150Q/150Q, and to a lesser extent in YAC128 mouse models. Less
severe andmore localized pathology was also observed in the YAC128
model (for review see [203]). In contrast to these studies, Godavarthi
and colleagues [204] found no differences in cytokine expression
(MCP-1, IL-6, IL-10, TNF-α, interferon-γ, IL-12) and microglia
numbers in 12-week-old R6/2 mice, at an age when these mice
show severe symptoms.
The anti-inﬂammatory tetracycline minocycline has been shown
to improve behavioral and neuropathological deﬁcits in R6/2 mice
[205,206] and was also protective in an excitotoxic rat model of HD
[207]. In a different excitotoxic model of HD (3-nitropropionic acid)
treatment with C5a receptor antagonists reduced neuropathology,
behavioural and motor deﬁcits [208].
Abnormalities in the kynurenic acid pathway are an interesting
aspect of HD pathology. Quinolinic acid and 3-hydroxykynurenine are
neurotoxic metabolites that are elevated in HD and in the R6/2, Hdh
150Q/150Q and YAC128 mouse models. The kynurenine pathway isD and interactions between Aβ, microglia and the complement system.
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microglia and astroglia may result in production of these excitotoxic
metabolites before morphological markers of glial activation are
apparent [209–211]. The data on activation of the inﬂammatory
system in transgenic HD mouse models are sparse and contradictory,
possibly due to considerable differences in the pathology between
different transgenic strains, but also due to the paucity of studies.
However, data in HD patients show that the inﬂammatory system is
activated very early and thus may be an important therapeutic target.
5. Summary
As stated in the introduction, the perfect animal model of a human
disease should reﬂect the symptoms, lesions and causes of the disease
[1]. Our review explored how transgenic mouse models of AD, PD and
HD matched these requirements in the particular area of neuroin-
ﬂammation. Possible mechanisms involving inﬂammatory responses
in transgenic mouse models are shown in Fig. 2.
Mousemodels of AD have been available for a number of years and
have been studied widely (for recent reviews comparing mouse
models and AD in general see: [1,8,9]). These transgenic mice develop
symptoms comparable to AD (memory and behavioral deﬁcits). They
build up Aβ deposits, one of the hallmarks of AD, but lack two others;
NFTs and overt neuronal death. Since APP and PS1 mutations do not
cause sporadic AD (the majority of AD cases), models with these
mutations reﬂect the cause of disease only for the subset of familial
cases. Evidence is readily available that Aβ deposition in AD mouse
models is accompanied by glial accumulation and activation, and, to
variable degrees, modulation of the levels of inﬂammatory cytokines
and complement activation. This inﬂammatory response is incom-
plete and less severe compared to AD.
There are several possible explanations: (i) neurodegenerative
diseases in humans take many years or even decades to develop; mice
may simply not get old enough to develop full-blown inﬂammation;
(ii) in most models human genes are introduced and human proteins
are expressed. Interactions with the mouse proteome may not reﬂect
the situation in humans. (iii) Different mechanisms of repair and
compensation may exist in long-lived organisms such as humans, and
interspecies differences in the complement system have been
reported [34,35].
Similarly to AD, only a fraction of PD cases is caused by mutations.
These mutations have been used to create mouse models. Compared
with AD transgenic models, the available PD models show less
behavioral deﬁcits and pathological changes. Only little evidence for
activation of the immune system is available. This may in part be due
to the fact that these models have been developed recently and only a
few studies have been conducted to investigate the involvement of
inﬂammation in the disease process.
Since HD is a hereditary disorder, models created using genes of
extended triplet repeats mirror the cause of the disease in humans.
Introduction of segments or the complete HD gene causes a range of
pathology from wide-spread, non-speciﬁc degeneration to mild
disease [203]. Again only little and conﬂicting information on the
involvement of inﬂammation in these mice can be found in the
literature.
The seeming lack of inﬂammatory changes in PD and HD mouse
models may be due to (i) the fact that the aggregated proteins in AD
are deposited extracellularly, while in HD (and in somemodels of PD),
pathological proteins aggregate intracellularly; (ii) that inﬂammatory
processes may play a lesser role in the mouse models and/or in
human PD and HD; or (iii) the current lack of studies focused on the
involvement of inﬂammation in these models.
In conclusion, transgenic models have been proven to be useful
tools in the exploration of molecular mechanisms of neurodegener-
ative disorders and in the discovery of potential therapeutic
strategies. Particularly in AD these transgenic models represent animprovement over previous toxic or lesion models. Especially
interesting are data in the ﬁeld of in-vivo multi photon imaging,
differential microglial activation and the promising results of
vaccination studies. The last example also demonstrates the impor-
tance of careful scrutiny when translating results from mouse models
into clinical application.
Like most models, the available transgenic mouse strains are
imperfect models of human neurodegenerative diseases. However,
further studies will lead to a continuously improving match with
human disorders for the development of useful therapeutic strategies.
Careful comparison with data from human pathology and studies on
other organisms, such as dogs or non-human primates [212] will be
the most useful additions to mouse models. The recent report
describing creation of the ﬁrst transgenic nonhuman primate line
[213] will hopefully encourage further efforts into the development of
new transgenic animal models of neurodegenerative disease that
more closely resemble human pathology, including neuroimmune
responses.
Acknowledgements
This research was supported by the Jack Brown and Family AD
Research Foundation, the Paciﬁc Alzheimer Research Foundation and
the Natural Sciences and Engineering Research Council of Canada.
References
[1] C. Duyckaerts, M.C. Potier, B. Delatour, Alzheimer disease models and human
neuropathology: similarities and differences, Acta Neuropathol. 115 (2008)
5–38.
[2] A.J. Rozemuller, W.A. van Gool, P. Eikelenboom, The neuroinﬂammatory
response in plaques and amyloid angiopathy in Alzheimer's disease: therapeutic
implications, Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 223–233.
[3] E.G. McGeer, A. Klegeris, P.L. McGeer, Inﬂammation, the complement system and
the diseases of aging, Neurobiol. Aging 26 (Suppl 1) (2005) 94–97.
[4] A. Klegeris, E.G. McGeer, P.L. McGeer, Therapeutic approaches to inﬂammation in
neurodegenerative disease, Curr. Opin. Neurol. 20 (2007) 351–357.
[5] I. Glezer, A.R. Simard, S. Rivest, Neuroprotective role of the innate immune
system by microglia, Neuroscience 147 (2007) 867–883.
[6] M. Grifﬁths, J.W. Neal, P. Gasque, Innate immunity and protective neuroin-
ﬂammation: new emphasis on the role of neuroimmune regulatory proteins,
Int. Rev. Neurobiol. 82 (2007) 29–55.
[7] C. Schwab, P.L. McGeer, Inﬂammatory aspects of Alzheimer disease and other
neurodegenerative disorders, J. Alzheimers Dis. 13 (2008) 359–369.
[8] D.A. Morrissette, A. Parachikova, K.N. Green, F.M. LaFerla, Relevance of
transgenic mouse models to human Alzheimer disease, J. Biol. Chem. 284
(2009) 6033–6037.
[9] D.R. Howlett, J.C. Richardson, The pathology of APP transgenic mice: a model of
Alzheimer's disease or simply overexpression of APP? Histol. Histopathol. 24
(2009) 83–100.
[10] S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, R. Kayed, R.
Metherate, M.P. Mattson, Y. Akbari, F.M. LaFerla, Triple-transgenic model of
Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic
dysfunction, Neuron 39 (2003) 409–421.
[11] A.P. Sjoberg, L.A. Trouw, A.M. Blom, Complement activation and inhibition: a
delicate balance, Trends Immunol. 30 (2009) 83–90.
[12] P.L. McGeer, E.G. McGeer, Complement proteins and complement inhibitors in
Alzheimer's disease, Res. Immunol. 143 (1992) 621–624.
[13] J. Rogers, J. Schultz, L. Brachova, L.F. Lue, S. Webster, B. Bradt, N.R. Cooper, D.E.
Moss, Complement activation and beta-amyloid-mediated neurotoxicity in
Alzheimer's disease, Res. Immunol. 143 (1992) 624–630.
[14] H. Jiang, D. Burdick, C.G. Glabe, C.W. Cotman, A.J. Tenner, beta-Amyloid activates
complement by binding to a speciﬁc region of the collagen-like domain of the
C1q A chain, J. Immunol. 152 (1994) 5050–5059.
[15] P. Tacnet-Delorme, S. Chevallier, G.J. Arlaud, Beta-amyloid ﬁbrils activate the C1
complex of complement under physiological conditions: evidence for a binding
site for A beta on the C1q globular regions, J. Immunol. 167 (2001) 6374–6381.
[16] B.M. Bradt, W.P. Kolb, N.R. Cooper, Complement-dependent proinﬂammatory
properties of the Alzheimer's disease beta-peptide, J. Exp. Med. 188 (1998)
431–438.
[17] D.A. Loefﬂer, D.M. Camp, D.A. Bennett, Plaque complement activation and
cognitive loss in Alzheimer's disease, J. Neuroinﬂammation 5 (2008) 9.
[18] K. Yasojima, C. Schwab, E.G. McGeer, P.L. McGeer, Up-regulated production and
activation of the complement system in Alzheimer's disease brain, Am. J. Pathol.
154 (1999) 927–936.
[19] H. Zanjani, C.E. Finch, C. Kemper, J. Atkinson, D. McKeel, J.C. Morris, J.L. Price,
Complement activation in very early Alzheimer disease, Alzheimer Dis. Assoc.
Disord. 19 (2005) 55–66.
899C. Schwab et al. / Biochimica et Biophysica Acta 1802 (2010) 889–902[20] L.A. Trouw, H.M. Nielsen, L. Minthon, E. Londos, G. Landberg, R. Veerhuis, S.
Janciauskiene, A.M. Blom, C4b-binding protein in Alzheimer's disease: binding to
Abeta1-42 and to dead cells, Mol. Immunol. 45 (2008) 3649–3660.
[21] K. Yasojima, E.G. McGeer, P.L. McGeer, Complement regulators C1 inhibitor and
CD59 do not signiﬁcantly inhibit complement activation in Alzheimer disease,
Brain Res. 833 (1999) 297–301.
[22] R. Fan, K. DeFilippis, W.E. Van Nostrand, Induction of complement proteins in a
mousemodel for cerebral microvascular A beta deposition, J. Neuroinﬂammation
4 (2007) 22.
[23] Y. Matsuoka, M. Picciano, B. Malester, J. LaFrancois, C. Zehr, J.M. Daeschner, J.A.
Olschowka, M.I. Fonseca, M.K. O'Banion, A.J. Tenner, C.A. Lemere, K. Duff,
Inﬂammatory responses to amyloidosis in a transgenic mouse model of
Alzheimer's disease, Am. J. Pathol. 158 (2001) 1345–1354.
[24] C. Schwab, M. Hosokawa, P.L. McGeer, Transgenic mice overexpressing amyloid
beta protein are an incomplete model of Alzheimer disease, Exp. Neurol. 188
(2004) 52–64.
[25] J. Zhou, M.I. Fonseca, K. Pisalyaput, A.J. Tenner, Complement C3 and C4
expression in C1q sufﬁcient and deﬁcient mouse models of Alzheimer's disease,
J. Neurochem. 106 (2008) 2080–2092.
[26] M.I. Fonseca, J. Zhou, M. Botto, A.J. Tenner, Absence of C1q leads to less
neuropathology in transgenic mouse models of Alzheimer's disease, J. Neurosci.
24 (2004) 6457–6465.
[27] M.I. Fonseca, R.R. Ager, S.H. Chu, O. Yazan, S.D. Sanderson, F.M. LaFerla, S.M.
Taylor, T.M. Woodruff, A.J. Tenner, Treatment with a C5aR antagonist decreases
pathology and enhances behavioral performance in murine models of
Alzheimer's disease, J. Immunol. 183 (2009) 1375–1383.
[28] M. Maier, Y. Peng, L. Jiang, T.J. Seabrook, M.C. Carroll, C.A. Lemere, Complement
C3 deﬁciency leads to accelerated amyloid beta plaque deposition and
neurodegeneration and modulation of the microglia/macrophage phenotype
in amyloid precursor protein transgenic mice, J. Neurosci. 28 (2008) 6333–6341.
[29] T. Wyss-Coray, F. Yan, A.H. Lin, J.D. Lambris, J.J. Alexander, R.J. Quigg, E. Masliah,
Prominent neurodegeneration and increased plaque formation in complement-
inhibited Alzheimer's mice, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10837–10842.
[30] N.S. Pillay, L.A. Kellaway, G.J. Kotwal, Early detection of memory deﬁcits and
memory improvement with vaccinia virus complement control protein in an
Alzheimer's disease model, Behav. Brain Res. 192 (2008) 173–177.
[31] D.A. Loefﬂer, Using animal models to determine the signiﬁcance of complement
activation in Alzheimer's disease, J. Neuroinﬂammation 1 (2004) 18.
[32] A.J. Tenner, M.I. Fonseca, The double-edged ﬂower: roles of complement protein
C1q in neurodegenerative diseases, Adv. Exp. Med. Biol. 586 (2006) 153–176.
[33] S.D. Webster, A.J. Tenner, T.L. Poulos, D.H. Cribbs, The mouse C1q A-chain
sequence alters beta-amyloid-induced complement activation, Neurobiol. Aging
20 (1999) 297–304.
[34] G.L. Ong, M.J. Mattes, Mouse strains with typical mammalian levels of
complement activity, J. Immunol. Methods 125 (1989) 147–158.
[35] R.O. Ebanks, D.E. Isenman, Mouse complement component C4 is devoid of
classical pathway C5 convertase subunit activity, Mol. Immunol. 33 (1996)
297–309.
[36] E.G. McGeer, P.L. McGeer, Brain inﬂammation in Alzheimer disease and the
therapeutic implications, Curr. Pharm. Des. 5 (1999) 821–836.
[37] W.J. Streit, R.E. Mrak, W.S. Grifﬁn, Microglia and neuroinﬂammation: a
pathological perspective, J. Neuroinﬂammation 1 (2004) 14.
[38] D.W. Dickson, S.C. Lee, L.A. Mattiace, S.H. Yen, C. Brosnan, Microglia and
cytokines in neurological disease, with special reference to AIDS and Alzheimer's
disease, Glia 7 (1993) 75–83.
[39] A. Klegeris, P.L. McGeer, A. Klegeris, P.L. McGeer, beta-amyloid protein enhances
macrophage production of oxygen free radicals and glutamate, J. Neurosci. Res.
49 (1997) 229–235.
[40] S.L. Yates, L.H. Burgess, J. Kocsis-Angle, J.M. Antal, M.D. Dority, P.B. Embury, A.M.
Piotrkowski, K.R. Brunden, Amyloid beta and amylin ﬁbrils induce increases in
proinﬂammatory cytokine and chemokine production by THP-1 cells andmurine
microglia, J. Neurochem. 74 (2000) 1017–1025.
[41] M.L. Block, L. Zecca, J.S. Hong, Microglia-mediated neurotoxicity: uncovering the
molecular mechanisms, Nat. Rev., Neurosci. 8 (2007) 57–69.
[42] U.K. Hanisch, H. Kettenmann, Microglia: active sensor and versatile effector cells
in the normal and pathologic brain, Nat. Neurosci. 10 (2007) 1387–1394.
[43] S.A. Frautschy, F. Yang, M. Irrizarry, B. Hyman, T.C. Saido, K. Hsiao, G.M. Cole,
Microglial response to amyloid plaques in APPsw transgenic mice, Am. J. Pathol.
152 (1998) 307–317.
[44] C. Sturchler-Pierrat, D. Abramowski, M. Duke, K.H. Wiederhold, C. Mistl, S.
Rothacher, B. Ledermann, K. Burki, P. Frey, P.A. Paganetti, C. Waridel, M.E. Calhoun,
M. Jucker, A. Probst, M. Staufenbiel, B. Sommer, Two amyloid precursor protein
transgenic mouse models with Alzheimer disease-like pathology, Proc. Natl. Acad.
Sci. U. S. A. 94 (1997) 13287–13292.
[45] B.J. Hock Jr., B.T. Lamb, Transgenic mouse models of Alzheimer's disease, Trends
Genet. 17 (2001) S7–12.
[46] S. Dudal, P. Krzywkowski, J. Paquette, C. Morissette, D. Lacombe, P. Tremblay, F.
Gervais, Inﬂammation occurs early during the Abeta deposition process in
TgCRND8 mice, Neurobiol. Aging 25 (2004) 861–871.
[47] D.W. Dickson, Microglia in Alzheimer's disease and transgenic models. How
close the ﬁt? Am. J. Pathol. 154 (1999) 1627–1631.
[48] Y. Yoshiyama, M. Higuchi, B. Zhang, S.M. Huang, N. Iwata, T.C. Saido, J. Maeda, T.
Suhara, J.Q. Trojanowski, V.M. Lee, Synapse loss and microglial activation
precede tangles in a P301S tauopathy mouse model, Neuron 53 (2007) 337–351.
[49] D.R. Howlett, K. Bowler, P.E. Soden, D. Riddell, J.B. Davis, J.C. Richardson, S.A.
Burbidge, M.I. Gonzalez, E.A. Irving, A. Lawman, G. Miglio, E.L. Dawson, E.R.Howlett, I. Hussain, Abeta deposition and related pathology in an APP x PS1
transgenic mouse model of Alzheimer's disease, Histol. Histopathol. 23 (2008)
67–76.
[50] M. Meyer-Luehmann, T.L. Spires-Jones, C. Prada, M. Garcia-Alloza, A. de Calignon,
A. Rozkalne, J. Koenigsknecht-Talboo, D.M. Holtzman, B.J. Bacskai, B.T. Hyman,
Rapid appearance and local toxicity of amyloid-beta plaques in amousemodel of
Alzheimer's disease, Nature 451 (2008) 720–724.
[51] T. Bolmont, F. Haiss, D. Eicke, R. Radde, C.A. Mathis, W.E. Klunk, S. Kohsaka, M.
Jucker, M.E. Calhoun, Dynamics of the microglial/amyloid interaction indicate a
role in plaque maintenance, J. Neurosci. 28 (2008) 4283–4292.
[52] M.N. Gordon, L.A. Holcomb, P.T. Jantzen, G. DiCarlo, D. Wilcock, K.W. Boyett, K.
Connor, J. Melachrino, J.P. O'Callaghan, D. Morgan, Time course of the
development of Alzheimer-like pathology in the doubly transgenic PS1+APP
mouse, Exp. Neurol. 173 (2002) 183–195.
[53] J. Tan, T. Town, F. Crawford, T. Mori, A. DelleDonne, R. Crescentini, D. Obregon, R.
A. Flavell, M.J. Mullan, Role of CD40 ligand in amyloidosis in transgenic
Alzheimer's mice, Nat. Neurosci. 5 (2002) 1288–1293.
[54] K.P. Townsend, T. Town, T. Mori, L.F. Lue, D. Shytle, P.R. Sanberg, D. Morgan, F.
Fernandez, R.A. Flavell, J. Tan, CD40 signaling regulates innate and adaptive
activation of microglia in response to amyloid beta-peptide, Eur. J. Immunol. 35
(2005) 901–910.
[55] D. Obregon, H. Hou, Y. Bai, W.V. Nikolic, T. Mori, D. Luo, J. Zeng, J. Ehrhart, F.
Fernandez, D. Morgan, B. Giunta, T. Town, J. Tan, CD40L disruption enhances
Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing
cerebral amyloid angiopathy and inﬂammation, Neurobiol. Dis. 29 (2008)
336–353.
[56] W.V. Nikolic, H. Hou, T. Town, Y. Zhu, B. Giunta, C.D. Sanberg, J. Zeng, D. Luo, J.
Ehrhart, T. Mori, P.R. Sanberg, J. Tan, Peripherally administered human umbilical
cord blood cells reduce parenchymal and vascular beta-amyloid deposits in
Alzheimer mice, Stem Cells Dev. 17 (2008) 423–439.
[57] V. Laporte, G. Ait-Ghezala, C.H. Volmar, C. Ganey, N. Ganey, M. Wood, M. Mullan,
CD40 ligation mediates plaque-associated tau phosphorylation in beta-amyloid
overproducing mice, Brain Res. 1231 (2008) 132–142.
[58] J. El Khoury, M. Toft, S.E. Hickman, T.K. Means, K. Terada, C. Geula, A.D. Luster,
Ccr2 deﬁciency impairs microglial accumulation and accelerates progression of
Alzheimer-like disease, Nat. Med. 13 (2007) 432–438.
[59] K.L. Richard, M. Filali, P. Prefontaine, S. Rivest, Toll-like receptor 2 acts as a
natural innate immune receptor to clear amyloid beta 1-42 and delay the
cognitive decline in a mouse model of Alzheimer's disease, J. Neurosci. 28 (2008)
5784–5793.
[60] N. Zelcer, N. Khanlou, R. Clare, Q. Jiang, E.G. Reed-Geaghan, G.E. Landreth, H.V.
Vinters, P. Tontonoz, Attenuation of neuroinﬂammation and Alzheimer's disease
pathology by liver x receptors, Proc. Natl. Acad. Sci. U. S. A. 104 (2007)
10601–10606.
[61] Q. Jiang, C.Y. Lee, S. Mandrekar, B. Wilkinson, P. Cramer, N. Zelcer, K. Mann, B.
Lamb, T.M.Willson, J.L. Collins, J.C. Richardson, J.D. Smith, T.A. Comery, D. Riddell,
D.M. Holtzman, P. Tontonoz, G.E. Landreth, ApoE promotes the proteolytic
degradation of Abeta, Neuron 58 (2008) 681–693.
[62] V. Boissonneault, M. Filali, M. Lessard, J. Relton, G. Wong, S. Rivest, Powerful
beneﬁcial effects of macrophage colony-stimulating factor on beta-amyloid
deposition and cognitive impairment in Alzheimer's disease, Brain 132 (2009)
1078–1092.
[63] K.E. Nichol, W.W. Poon, A.I. Parachikova, D.H. Cribbs, C.G. Glabe, C.W. Cotman,
Exercise alters the immune proﬁle in Tg2576 Alzheimer mice toward a response
coincident with improved cognitive performance and decreased amyloid, J.
Neuroinﬂammation 5 (2008) 13.
[64] K. Farber, G. Cheung, D. Mitchell, R. Wallis, E. Weihe, W. Schwaeble, H.
Kettenmann, C1q, the recognition subcomponent of the classical pathway of
complement, drives microglial activation, J. Neurosci. Res. 87 (2009)
644–652.
[65] O. Butovsky, M. Koronyo-Hamaoui, G. Kunis, E. Ophir, G. Landa, H. Cohen, M.
Schwartz, Glatiramer acetate ﬁghts against Alzheimer's disease by inducing
dendritic-like microglia expressing insulin-like growth factor 1, Proc. Natl. Acad.
Sci. U. S. A. 103 (2006) 11784–11789.
[66] D.L. Herber, M. Mercer, L.M. Roth, K. Symmonds, J. Maloney, N. Wilson, M.J.
Freeman, D. Morgan, M.N. Gordon, Microglial activation is required for Abeta
clearance after intracranial injection of lipopolysaccharide in APP transgenic
mice, J. Neuroimmune Pharmacol. 2 (2007) 222–231.
[67] R. Fan, F. Xu, M.L. Previti, J. Davis, A.M. Grande, J.K. Robinson, W.E. Van Nostrand,
Minocycline reduces microglial activation and improves behavioral deﬁcits in a
transgenic model of cerebral microvascular amyloid, J. Neurosci. 27 (2007)
3057–3063.
[68] F.C. Crawford, M. Wood, S. Ferguson, V.S. Mathura, B. Faza, S. Wilson, T. Fan, B.
O'Steen, G. Ait-Ghezala, R. Hayes, M.J. Mullan, Genomic analysis of response to
traumatic brain injury in a mouse model of Alzheimer's disease (APPsw),
Brain Res. 1185 (2007) 45–58.
[69] S. Jimenez, D. Baglietto-Vargas, C. Caballero, I. Moreno-Gonzalez, M. Torres, R.
Sanchez-Varo, D. Ruano, M. Vizuete, A. Gutierrez, J. Vitorica, Inﬂammatory
response in the hippocampus of PS1M146L/APP751SL mouse model of
Alzheimer's disease: age-dependent switch in the microglial phenotype from
alternative to classic, J. Neurosci. 28 (2008) 11650–11661.
[70] W.J. Streit, Microglial senescence: does the brain's immune system have an
expiration date? Trends Neurosci. 29 (2006) 506–510.
[71] B. Giunta, F. Fernandez, W.V. Nikolic, D. Obregon, E. Rrapo, T. Town, J. Tan,
Inﬂammaging as a prodrome to Alzheimer's disease, J. Neuroinﬂammation 5
(2008) 51.
900 C. Schwab et al. / Biochimica et Biophysica Acta 1802 (2010) 889–902[72] A.R. Simard, S. Rivest, Bone marrow stem cells have the ability to populate the
entire central nervous system into fully differentiated parenchymal microglia,
FASEB J. 18 (2004) 998–1000.
[73] A.R. Simard, D. Soulet, G. Gowing, J.P. Julien, S. Rivest, Bone marrow-derived
microglia play a critical role in restricting senile plaque formation in Alzheimer's
disease, Neuron 49 (2006) 489–502.
[74] T. Town, Y. Laouar, C. Pittenger, T. Mori, C.A. Szekely, J. Tan, R.S. Duman, R.A.
Flavell, Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzhei-
mer-like pathology, Nat. Med. 14 (2008) 681–687.
[75] O. Butovsky, G. Kunis, M. Koronyo-Hamaoui, M. Schwartz, Selective ablation of
bone marrow-derived dendritic cells increases amyloid plaques in a mouse
Alzheimer's disease model, Eur. J. Neurosci. 26 (2007) 413–416.
[76] B. Ajami, J.L. Bennett, C. Krieger, W. Tetzlaff, F.M. Rossi, Local self-renewal
can sustain CNS microglia maintenance and function throughout adult life,
Nat. Neurosci. 10 (2007) 1538–1543.
[77] C.A. Lemere, E.T. Spooner, J.F. Leverone, C. Mori, M. Iglesias, J.K. Bloom, T.J.
Seabrook, Amyloid-beta immunization in Alzheimer's disease transgenic mouse
models and wildtype mice, Neurochem. Res. 28 (2003) 1017–1027.
[78] D.M. Wilcock, C.A. Colton, Anti-amyloid-beta immunotherapy in Alzheimer's
disease: relevance of transgenic mouse studies to clinical trials, J. Alzheimers Dis.
15 (2008) 555–569.
[79] D. Morgan, The role of microglia in antibody-mediated clearance of amyloid-beta
from the brain, CNS Neurol. Disord. Drug Targets 8 (2009) 7–15.
[80] S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Grifﬁth, N.C. Fox, L. Eisner, L. Kirby,
M.B. Rovira, F. Forette, J.M. Orgogozo, Clinical effects of Abeta immunization
(AN1792) in patients with AD in an interrupted trial, Neurology 64 (2005)
1553–1562.
[81] J.A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, R.O. Weller,
Neuropathology of human Alzheimer disease after immunization with amy-
loid-beta peptide: a case report, Nat. Med. 9 (2003) 448–452.
[82] D. Morgan, Modulation of microglial activation state following passive
immunization in amyloid depositing transgenic mice, Neurochem. Int. 49
(2006) 190–194.
[83] D.M. Wilcock, S.K. Munireddy, A. Rosenthal, K.E. Ugen, M.N. Gordon, D.
Morgan, Microglial activation facilitates Abeta plaque removal following
intracranial anti-Abeta antibody administration, Neurobiol. Dis. 15 (2004)
11–20.
[84] D.M. Wilcock, M.N. Gordon, K.E. Ugen, P.E. Gottschall, G. DiCarlo, C. Dickey, K.W.
Boyett, P.T. Jantzen, K.E. Connor, J. Melachrino, J. Hardy, D. Morgan, Number of
Abeta inoculations in APP+PS1 transgenic mice inﬂuences antibody titers,
microglial activation, and congophilic plaque levels, DNA Cell Biol. 20 (2001)
731–736.
[85] J. Koenigsknecht-Talboo, M.Meyer-Luehmann, M. Parsadanian, M. Garcia-Alloza,
M.B. Finn, B.T. Hyman, B.J. Bacskai, D.M. Holtzman, Rapid microglial response
around amyloid pathology after systemic anti-Abeta antibody administration in
PDAPP mice, J. Neurosci. 28 (2008) 14156–14164.
[86] F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, T. Guido, K. Hoenow,
K. Hu, K. Johnson-Wood, K. Khan, D. Kholodenko, C. Lee, M. Lee, R. Motter, M.
Nguyen, A. Reed, D. Schenk, P. Tang, N. Vasquez, P. Seubert, T. Yednock, Epitope
and isotype speciﬁcities of antibodies to beta -amyloid peptide for protection
against Alzheimer's disease-like neuropathology, Proc. Natl. Acad. Sci. U. S. A.
100 (2003) 2023–2028.
[87] A.J. Gray, G. Sakaguchi, C. Shiratori, A.G. Becker, J. LaFrancois, P.S. Aisen, K. Duff, Y.
Matsuoka, Antibody against C-terminal Abeta selectively elevates plasma Abeta,
NeuroReport 18 (2007) 293–296.
[88] Y. Okura, K. Kohyama, I.K. Park, Y. Matsumoto, Nonviral DNA vaccination
augments microglial phagocytosis of beta-amyloid deposits as a major clearance
pathway in an Alzheimer disease mouse model, J. Neuropathol. Exp. Neurol. 67
(2008) 1063–1071.
[89] A. Mouri, Y. Noda, H. Hara, H. Mizoguchi, T. Tabira, T. Nabeshima, Oral
vaccination with a viral vector containing Abeta cDNA attenuates age-related
Abeta accumulation and memory deﬁcits without causing inﬂammation in a
mouse Alzheimer model, FASEB J. 21 (2007) 2135–2148.
[90] M. Garcia-Alloza, B.J. Ferrara, S.A. Dodwell, G.A. Hickey, B.T. Hyman, B.J. Bacskai,
A limited role for microglia in antibody mediated plaque clearance in APP mice,
Neurobiol. Dis. 28 (2007) 286–292.
[91] C. Colton, S. Wilt, D. Gilbert, O. Chernyshev, J. Snell, M. Dubois-Dalcq, Species
differences in the generation of reactive oxygen species bymicroglia, Mol. Chem.
Neuropathol. 28 (1996) 15–20.
[92] H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P.
Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S. Grifﬁn, H.
Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I.R. Mackenzie, P.L. McGeer, M.K.
O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W.
Streit, R. Strohmeyer, I. Tooyoma, F.L. Van Muiswinkel, R. Veerhuis, D. Walker, S.
Webster, B. Wegrzyniak, G. Wenk, T. Wyss-Coray, Inﬂammation and Alzheimer's
disease, Neurobiol. Aging 21 (2000) 383–421.
[93] R.E. Mrak, J.G. Sheng, W.S. Grifﬁn, Glial cytokines in Alzheimer's disease: review
and pathogenic implications, Hum. Pathol. 26 (1995) 816–823.
[94] W.C. Benzing, J.R. Wujek, E.K. Ward, D. Shaffer, K.H. Ashe, S.G. Younkin, K.R.
Brunden, Evidence for glial-mediated inﬂammation in aged APP(SW) transgenic
mice, Neurobiol. Aging 20 (1999) 581–589.
[95] J. Apelt, R. Schliebs, Beta-amyloid-induced glial expression of both pro- and anti-
inﬂammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with
Alzheimer plaque pathology, Brain Res. 894 (2001) 21–30.
[96] N. Abbas, I. Bednar, E. Mix, S. Marie, D. Paterson, A. Ljungberg, C. Morris, B.
Winblad, A. Nordberg, J. Zhu, Up-regulation of the inﬂammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP
(SWE) transgenic mice, J. Neuroimmunol. 126 (2002) 50–57.
[97] N.S. Patel, D. Paris, V. Mathura, A.N. Quadros, F.C. Crawford, M.J. Mullan,
Inﬂammatory cytokine levels correlate with amyloid load in transgenic mouse
models of Alzheimer's disease, J. Neuroinﬂammation 2 (2005) 9.
[98] M.C. Janelsins, M.A. Mastrangelo, S. Oddo, F.M. LaFerla, H.J. Federoff, W.J.
Bowers, Early correlation of microglial activation with enhanced tumor necrosis
factor-alpha and monocyte chemoattractant protein-1 expression speciﬁcally
within the entorhinal cortex of triple transgenic Alzheimer's disease mice, J.
Neuroinﬂammation 2 (2005) 23.
[99] F.E. McAlpine, J.K. Lee, A.S. Harms, K.A. Ruhn, M. Blurton-Jones, J. Hong, P. Das,
T.E. Golde, F.M. LaFerla, S. Oddo, A. Blesch, M.G. Tansey, Inhibition of soluble
TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque
amyloid-associated neuropathology, Neurobiol. Dis. 34 (2009) 163–177.
[100] P. He, Z. Zhong, K. Lindholm, L. Berning, W. Lee, C. Lemere, M. Staufenbiel, R. Li, Y.
Shen, Deletion of tumor necrosis factor death receptor inhibits amyloid beta
generation and prevents learning andmemory deﬁcits in Alzheimer's mice, J. Cell
Biol. 178 (2007) 829–841.
[101] M. Yamamoto, T. Kiyota, M. Horiba, J.L. Buescher, S.M. Walsh, H.E. Gendelman, T.
Ikezu, Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta
plaque deposition and beta-secretase expression in Swedish mutant APP
transgenic mice, Am. J. Pathol. 170 (2007) 680–692.
[102] J.J. Jin, H.D. Kim, J.A. Maxwell, L. Li, K. Fukuchi, Toll-like receptor 4-dependent
upregulation of cytokines in a transgenic mouse model of Alzheimer's disease,
J. Neuroinﬂammation 5 (2008) 23.
[103] S.S. Shaftel, S. Kyrkanides, J.A. Olschowka, J.N. Miller, R.E. Johnson, M.K. O'Banion,
Sustained hippocampal IL-1 beta overexpression mediates chronic neuroin-
ﬂammation and ameliorates Alzheimer plaque pathology, J. Clin. Invest. 117
(2007) 1595–1604.
[104] T. Wyss-Coray, C. Lin, F. Yan, G.Q. Yu, M. Rohde, L. McConlogue, E. Masliah, L.
Mucke, TGF-beta1 promotes microglial amyloid-beta clearance and reduces
plaque burden in transgenic mice, Nat. Med. 7 (2001) 612–618.
[105] S. Lesne, F. Docagne, C. Gabriel, G. Liot, D.K. Lahiri, L. Buee, L. Plawinski, A.
Delacourte, E.T. MacKenzie, A. Buisson, D. Vivien, Transforming growth factor-
beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice,
J. Biol. Chem. 278 (2003) 18408–18418.
[106] M. Yamamoto, M. Horiba, J.L. Buescher, D. Huang, H.E. Gendelman, R.M.
Ransohoff, T. Ikezu, Overexpression of monocyte chemotactic protein-1/CCL2
in beta-amyloid precursor protein transgenic mice show accelerated diffuse
beta-amyloid deposition, Am. J. Pathol. 166 (2005) 1475–1485.
[107] T. Kiyota, M. Yamamoto, B. Schroder, M.T. Jacobsen, R.J. Swan, M.P. Lambert, W.L.
Klein, H.E. Gendelman, R.M. Ransohoff, T. Ikezu, AAV1/2-mediated CNS gene
delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloid-
osis, and learning impairment of APP/PS1 mice, Mol. Ther. 17 (2009) 803–809.
[108] B.A. in't Veld, A. Ruitenberg, A. Hofman, B.H. Stricker, M.M. Breteler,
Antihypertensive drugs and incidence of dementia: the Rotterdam Study,
Neurobiol. Aging 22 (2001) 407–412.
[109] W.F. Stewart, C. Kawas, M. Corrada, E.J. Metter, Risk of Alzheimer's disease and
duration of NSAID use, Neurology 48 (1997) 626–632.
[110] P.L. McGeer, E.G. McGeer, NSAIDs and Alzheimer disease: epidemiological,
animal model and clinical studies, Neurobiol. Aging 28 (2007) 639–647.
[111] S.C. Vlad, D.R. Miller, N.W. Kowall, D.T. F elson, Protective effects of NSAIDs on
the development of Alzheimer disease, Neurology 70 (2008) 1672–1677.
[112] G.P. Lim, F. Yang, T. Chu, P. Chen, W. Beech, B. Teter, T. Tran, O. Ubeda, K.H. Ashe,
S.A. Frautschy, G.M. Cole, Ibuprofen suppresses plaque pathology and inﬂam-
mation in a mouse model for Alzheimer's disease, J. Neurosci. 20 (2000)
5709–5714.
[113] Q. Yan, J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A.L. Biere, M. Citron, G. Landreth,
Anti-inﬂammatory drug therapy alters beta-amyloid processing and deposition
in an animal model of Alzheimer's disease, J. Neurosci. 23 (2003) 7504–7509.
[114] P.T. Jantzen, K.E. Connor, G. DiCarlo, G.L. Wenk, J.L. Wallace, A.M. Rojiani, D.
Coppola, D. Morgan, M.N. Gordon, Microglial activation and beta -amyloid
deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-
inﬂammatory drug in amyloid precursor protein plus presenilin-1 transgenic
mice, J. Neurosci. 22 (2002) 2246–2254.
[115] T. van Groen, I. Kadish, Transgenic AD model mice, effects of potential anti-AD
treatments on inﬂammation and pathology, Brain Res. Brain Res. Rev. 48 (2005)
370–378.
[116] T. Kukar, S. Prescott, J.L. Eriksen, V. Holloway, M.P. Murphy, E.H. Koo, T.E. Golde,
M.M. Nicolle, Chronic administration of R-ﬂurbiprofen attenuates learning
impairments in transgenic amyloid precursor protein mice, BMC Neurosci.
8 (2007) 54.
[117] M.T. Heneka, M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, C. Kuiperi,
K. O'Banion, T. Klockgether, F. Van Leuven, G.E. Landreth, Acute treatment with
the PPARgamma agonist pioglitazone and ibuprofen reduces glial inﬂammation
and Abeta1-42 levels in APPV717I transgenic mice, Brain 128 (2005) 1442–1453.
[118] T. Morihara, B. Teter, F. Yang, G.P. Lim, S. Boudinot, F.D. Boudinot, S.A. Frautschy,
G.M. Cole, Ibuprofen suppresses interleukin-1beta induction of pro-amyloido-
genic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology
in Alzheimer's models, Neuropsychopharmacology 30 (2005) 1111–1120.
[119] A.C. McKee, I. Carreras, L. Hossain, H. Ryu, W.L. Klein, S. Oddo, F.M. LaFerla, B.G.
Jenkins, N.W. Kowall, A. Dedeoglu, Ibuprofen reduces Abeta, hyperphosphory-
lated tau and memory deﬁcits in Alzheimer mice, Brain Res. 1207 (2008)
225–236.
[120] T.A. Lanz, G.J. Fici, K.M. Merchant, Lack of speciﬁc amyloid-beta(1-42)
suppression by nonsteroidal anti-inﬂammatory drugs in young, plaque-free
901C. Schwab et al. / Biochimica et Biophysica Acta 1802 (2010) 889–902Tg2576 mice and in guinea pig neuronal cultures, J. Pharmacol. Exp. Ther. 312
(2005) 399–406.
[121] J. Quinn, T. Montine, J. Morrow, W.R. Woodward, D. Kulhanek, F. Eckenstein,
Inﬂammation and cerebral amyloidosis are disconnected in an animal model of
Alzheimer's disease, J. Neuroimmunol. 137 (2003) 32–41.
[122] S. Sung, H. Yang, K. Uryu, E.B. Lee, L. Zhao, D. Shineman, J.Q. Trojanowski, V.M.
Lee, D. Pratico, Modulation of nuclear factor-kappa B activity by indomethacin
inﬂuences A beta levels but not A beta precursor protein metabolism in a model
of Alzheimer's disease, Am. J. Pathol. 165 (2004) 2197–2206.
[123] E. Dvir, A. Elman, D. Simmons, I. Shapiro, R. Duvdevani, A. Dahan, A. Hoffman, J.E.
Friedman, DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal
antiinﬂammatory drug for analgesia and Alzheimer's disease therapy, CNS Drug
Rev. 13 (2007) 260–277.
[124] T. Kukar, M.P. Murphy, J.L. Eriksen, S.A. Sagi, S. Weggen, T.E. Smith, T. Ladd, M.A.
Khan, R. Kache, J. Beard, M. Dodson, S. Merit, V.V. Ozols, P.Z. Anastasiadis, P. Das,
A. Fauq, E.H. Koo, T.E. Golde, Diverse compounds mimic Alzheimer disease-
causing mutations by augmenting Abeta42 production, Nat. Med. 11 (2005)
545–550.
[125] J.J. Hoozemans, J.M. Rozemuller, E.S. van Haastert, R. Veerhuis, P. Eikelenboom,
Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease
pathology, Curr. Pharm. Des. 14 (2008) 1419–1427.
[126] J.R. Vane, R.M. Botting, Mechanism of action of antiinﬂammatory drugs, Int. J.
Tissue React. 20 (1998) 3–15.
[127] S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, C.U. Pietrzik, K.A. Findlay, T.E.
Smith, M.P. Murphy, T. Bulter, D.E. Kang, N. Marquez-Sterling, T.E. Golde, E.H.
Koo, A subset of NSAIDs lower amyloidogenic Abeta42 independently of
cyclooxygenase activity, Nature 414 (2001) 212–216.
[128] A. Lleo, E. Galea, M. Sastre, Molecular targets of non-steroidal anti-inﬂammatory
drugs in neurodegenerative diseases, Cell. Mol. Life Sci. 64 (2007) 1403–1418.
[129] P.L. McGeer, S. Itagaki, B.E. Boyes, E.G. McGeer, Reactive microglia are positive for
HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains,
Neurology 38 (1988) 1285–1291.
[130] E.C. Hirsch, S. Hunot, Neuroinﬂammation in Parkinson's disease: a target for
neuroprotection? Lancet Neurol. 8 (2009) 382–397.
[131] P.S. Whitton, Inﬂammation as a causative factor in the aetiology of Parkinson's
disease, Br. J. Pharmacol. 150 (2007) 963–976.
[132] P.L. McGeer, E.G. McGeer, Glial reactions in Parkinson's disease, Mov. Disord. 23
(2008) 474–483.
[133] J.W. Langston, P. Ballard, J.W. Tetrud, I. Irwin, Chronic Parkinsonism in
humans due to a product of meperidine-analog synthesis, Science 219 (1983)
979–980.
[134] J.W. Langston, L.S. Forno, J. Tetrud, A.G. Reeves, J.A. Kaplan, D. Karluk, Evidence of
active nerve cell degeneration in the substantia nigra of humans years after 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure, Ann. Neurol. 46 (1999)
598–605.
[135] P.L. McGeer, C. Schwab, A. Parent, D. Doudet, Presence of reactive microglia in
monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine administration, Ann. Neurol. 54 (2003) 599–604.
[136] J. Miklossy, D.D. Doudet, C. Schwab, S. Yu, E.G. McGeer, P.L. McGeer, Role of
ICAM-1 in persisting inﬂammation in Parkinson disease and MPTP monkeys,
Exp. Neurol. 197 (2006) 275–283.
[137] P. Jenner, Functional models of Parkinson's disease: a valuable tool in the
development of novel therapies, Ann. Neurol. (2008) 64.
[138] S.M. Fleming, P.O. Fernagut, M.F. Chesselet, Genetic mouse models of
parkinsonism: strengths and limitations, NeuroRx 2 (2005) 495–503.
[139] B.K. Harvey, Y. Wang, B.J. Hoffer, Transgenic rodent models of Parkinson's
disease, Acta Neurochir. Suppl. 101 (2008) 89–92.
[140] M. Terzioglu, D. Galter, Parkinson's disease: genetic versus toxin-induced rodent
models, FEBS J. 275 (2008) 1384–1391.
[141] O. von Bohlen und Halbach, Modeling neurodegenerative diseases in vivo
review, Neurodegener. Dis. 2 (2005) 313–320.
[142] M.C. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, S. Lincoln,
C. Levecque, L. Larvor, J. Andrieux, M. Hulihan, N. Waucquier, L. Defebvre, P.
Amouyel, M. Farrer, A. Destee, Alpha-synuclein locus duplication as a cause of
familial Parkinson's disease, Lancet 364 (2004) 1167–1169.
[143] P. Ibanez, S. Lesage, S. Janin, E. Lohmann, F. Durif, A. Destee, A.M. Bonnet, C.
Brefel-Courbon, S. Heath, D. Zelenika, Y. Agid, A. Durr, A. Brice, Alpha-synuclein
gene rearrangements in dominantly inherited parkinsonism: frequency, phe-
notype, and mechanisms, Arch. Neurol. 66 (2009) 102–108.
[144] P. Ibanez, A.M. Bonnet, B. Debarges, E. Lohmann, F. Tison, P. Pollak, Y. Agid, A.
Durr, A. Brice, Causal relation between alpha-synuclein gene duplication and
familial Parkinson's disease, Lancet 364 (2004) 1169–1171.
[145] A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M.
Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson,
D. Maraganore, C. Adler, M.R. Cookson, M. Muenter, M. Baptista, D. Miller, J.
Blancato, J. Hardy, K. Gwinn-Hardy, alpha-Synuclein locus triplication causes
Parkinson's disease, Science 302 (2003) 841.
[146] E. Masliah, E. Rockenstein, I. Veinbergs, M. Mallory, M. Hashimoto, A. Takeda, Y.
Sagara, A. Sisk, L. Mucke, Dopaminergic loss and inclusion body formation in
alpha-synuclein mice: implications for neurodegenerative disorders, Science
287 (2000) 1265–1269.
[147] M.F. Chesselet, In vivo alpha-synuclein overexpression in rodents: a useful
model of Parkinson's disease? Exp. Neurol. 209 (2008) 22–27.
[148] M.F. Chesselet, S. Fleming, F. Mortazavi, B. Meurers, Strengths and limitations of
genetic mouse models of Parkinson's disease, Parkinsonism Relat. Disord. 14
(2008).[149] P.O. Fernagut, C.B. Hutson, S.M. Fleming, N.A. Tetreaut, J. Salcedo, E. Masliah, M.F.
Chesselet, Behavioral and histopathological consequences of paraquat intoxica-
tion in mice: effects of alpha-synuclein over-expression, Synapse 61 (2007)
991–1001.
[150] H. van der Putten, K.H. Wiederhold, A. Probst, S. Barbieri, C. Mistl, S. Danner, S.
Kauffmann, K. Hofele, W.P. Spooren, M.A. Ruegg, S. Lin, P. Caroni, B. Sommer,
M. Tolnay, G. Bilbe, Neuropathology in mice expressing human alpha-
synuclein, J. Neurosci. 20 (2000) 6021–6029.
[151] B.I. Giasson, J.E. Duda, S.M. Quinn, B. Zhang, J.Q. Trojanowski, V.M. Lee, Neuronal
alpha-synucleinopathy with severe movement disorder in mice expressing A53T
human alpha-synuclein, Neuron 34 (2002) 521–533.
[152] M.K. Lee, W. Stirling, Y. Xu, X. Xu, D. Qui, A.S. Mandir, T.M. Dawson, N.G.
Copeland, N.A. Jenkins, D.L. Price, Human alpha-synuclein-harboring familial
Parkinson's disease-linked Ala-53 –N Thr mutation causes neurodegenerative
disease with alpha-synuclein aggregation in transgenic mice, Proc. Natl. Acad.
Sci. U. S. A. 99 (2002) 8968–8973.
[153] S. Gispert, D. Del Turco, L. Garrett, A. Chen, D.J. Bernard, J. Hamm-Clement, H.W.
Korf, T. Deller, H. Braak, G. Auburger, R.L. Nussbaum, Transgenic mice expressing
mutant A53T human alpha-synuclein show neuronal dysfunction in the absence
of aggregate formation, Mol. Cell. Neurosci. 24 (2003) 419–429.
[154] T. Gomez-Isla, M.C. Irizarry, A. Mariash, B. Cheung, O. Soto, S. Schrump, J. Sondel,
L. Kotilinek, J. Day, M.A. Schwarzschild, J.H. Cha, K. Newell, D.W. Miller, K. Ueda,
A.B. Young, B.T. Hyman, K.H. Ashe, Motor dysfunction and gliosis with preserved
dopaminergic markers in human alpha-synuclein A30P transgenic mice,
Neurobiol. Aging 24 (2003) 245–258.
[155] X. Su, K.A. Maguire-Zeiss, R. Giuliano, L. Prifti, K. Venkatesh, H.J. Federoff,
Synuclein activates microglia in a model of Parkinson's disease, Neurobiol. Aging
29 (2008) 1690–1701.
[156] G.K. Tofaris, P. Garcia Reitbock, T. Humby, S.L. Lambourne, M. O'Connell, B.
Ghetti, H. Gossage, P.C. Emson, L.S. Wilkinson, M. Goedert, M.G. Spillantini,
Pathological changes in dopaminergic nerve cells of the substantia nigra and
olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120):
implications for Lewy body disorders, J. Neurosci. 26 (2006) 3942–3950.
[157] M. Wakamatsu, A. Ishii, S. Iwata, J. Sakagami, Y. Ukai, M. Ono, D. Kanbe, S.
Muramatsu, K. Kobayashi, T. Iwatsubo, M. Yoshimoto, Selective loss of nigral
dopamine neurons induced by overexpression of truncated human alpha-
synuclein in mice, Neurobiol. Aging 29 (2008) 574–585.
[158] N. Stefanova, M. Reindl, M. Neumann, P.J. Kahle, W. Poewe, G.K. Wenning,
Microglial activation mediates neurodegeneration related to oligodendroglial
alpha-synucleinopathy: implications for multiple system atrophy, Mov. Disord.
22 (2007) 2196–2203.
[159] H.M. Gao, P.T. Kotzbauer, K. Uryu, S. Leight, J.Q. Trojanowski, V.M. Lee,
Neuroinﬂammation and oxidation/nitration of alpha-synuclein linked to
dopaminergic neurodegeneration, J. Neurosci. 28 (2008) 7687–7698.
[160] S.A. Austin, A.M. Floden, E.J. Murphy, C.K. Combs, Alpha-synuclein expression
modulates microglial activation phenotype, J. Neurosci. 26 (2006) 10558–10563.
[161] E. Masliah, E. Rockenstein, A. Adame, M. Alford, L. Crews, M. Hashimoto, P.
Seubert, M. Lee, J. Goldstein, T. Chilcote, D. Games, D. Schenk, Effects of alpha-
synuclein immunization in a mouse model of Parkinson's disease, Neuron 46
(2005) 857–868.
[162] A. Klegeris, B.I. Giasson, H. Zhang, J. Maguire, S. Pelech, P.L. McGeer, Alpha-
synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human
astrocytes and astrocytoma cells, FASEB J. 20 (2006) 2000–2008.
[163] A. Klegeris, S. Pelech, B.I. Giasson, J. Maguire, H. Zhang, E.G. McGeer, P.L. McGeer,
Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and
microglia, Neurobiol. Aging 29 (2008) 739–752.
[164] J. Liu, J.P. Zhang, M. Shi, T. Quinn, J. Bradner, R. Beyer, S. Chen, J. Zhang, Rab11a
and HSP90 regulate recycling of extracellular alpha-synuclein, J. Neurosci. 29
(2009) 1480–1485.
[165] W. Zhang, S. Dallas, D. Zhang, J.P. Guo, H. Pang, B. Wilson, D.S. Miller, B. Chen, W.
Zhang, P.L. McGeer, J.S. Hong, J. Zhang, Microglial PHOX and Mac-1 are essential
to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T
mutant alpha-synuclein, Glia 55 (2007) 1178–1188.
[166] W. Zhang, T. Wang, Z. Pei, D.S. Miller, X. Wu, M.L. Block, B. Wilson, W. Zhang, Y.
Zhou, J.S. Hong, J. Zhang, Aggregated alpha-synuclein activates microglia: a
process leading to disease progression in Parkinson's disease, FASEB J. 19 (2005)
533–542.
[167] L. Chen, B. Cagniard, T. Mathews, S. Jones, H.C. Koh, Y. Ding, P.M. Carvey, Z. Ling,
U.J. Kang, X. Zhuang, Age-dependent motor deﬁcits and dopaminergic
dysfunction in DJ-1 null mice, J. Biol. Chem. 280 (2005) 21418–21426.
[168] M.S. Goldberg, A. Pisani, M. Haburcak, T.A. Vortherms, T. Kitada, C. Costa, Y. Tong,
G. Martella, A. Tscherter, A. Martins, G. Bernardi, B.L. Roth, E.N. Pothos, P.
Calabresi, J. Shen, Nigrostriatal dopaminergic deﬁcits and hypokinesia caused by
inactivation of the familial Parkinsonism-linked gene DJ-1. [see comment],
Neuron 45 (2005) 489–496.
[169] R.H. Kim, P.D. Smith, H. Aleyasin, S. Hayley, M.P. Mount, S. Pownall, A.
Wakeham, A.J. You-Ten, S.K. Kalia, P. Horne, D. Westaway, A.M. Lozano, H.
Anisman, D.S. Park, T.W. Mak, Hypersensitivity of DJ-1-deﬁcient mice to 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress,
Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5215–5220.
[170] T.C. Frank-Cannon, T. Tran, K.A. Ruhn, T.N. Martinez, J. Hong, M. Marvin, M.
Hartley, I. Trevino, D.E. O'Brien, B. Casey, M.S. Goldberg, M.G. Tansey, Parkin
deﬁciency increases vulnerability to inﬂammation-related nigral degeneration,
J. Neurosci. 28 (2008) 10825–10834.
[171] M.S. Goldberg, S.M. Fleming, J.J. Palacino, C. Cepeda, H.A. Lam, A. Bhatnagar, E.G.
Meloni, N. Wu, L.C. Ackerson, G.J. Klapstein, M. Gajendiran, B.L. Roth, M.F.
902 C. Schwab et al. / Biochimica et Biophysica Acta 1802 (2010) 889–902Chesselet, N.T. Maidment, M.S. Levine, J. Shen, Parkin-deﬁcient mice exhibit
nigrostriatal deﬁcits but not loss of dopaminergic neurons, J. Biol. Chem. 278
(2003) 43628–43635.
[172] T. Kitada, A. Pisani, D.R. Porter, H. Yamaguchi, A. Tscherter, G. Martella, P. Bonsi,
C. Zhang, E.N. Pothos, J. Shen, Impaired dopamine release and synaptic plasticity
in the striatum of PINK1-deﬁcient mice, Proc. Natl. Acad. Sci. U. S. A. 104 (2007)
11441–11446.
[173] H. Zhou, B.H. Falkenburger, J.B. Schulz, K. Tieu, Z. Xu, X.G. Xia, Silencing of the
Pink1 gene expression by conditional RNAi does not induce dopaminergic
neuron death in mice, Int. J. Biol. Sci. 3 (2007) 242–250.
[174] J.M. Itier, P. Ibanez, M.A. Mena, N. Abbas, C. Cohen-Salmon, G.A. Bohme, M.
Laville, J. Pratt, O. Corti, L. Pradier, G. Ret, C. Joubert, M. Periquet, F. Araujo, J.
Negroni, M.J. Casarejos, S. Canals, R. Solano, A. Serrano, E. Gallego, M. Sanchez, P.
Deneﬂe, J. Benavides, G. Tremp, T.A. Rooney, A. Brice, J. Garcia de Yebenes, Parkin
gene inactivation alters behaviour and dopamine neurotransmission in the
mouse, Hum. Mol. Genet. 12 (2003) 2277–2291.
[175] R. Von Coelln, B. Thomas, J.M. Savitt, K.L. Lim, M. Sasaki, E.J. Hess, V.L. Dawson, T.
M. Dawson, Loss of locus coeruleus neurons and reduced startle in parkin null
mice, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10744–10749.
[176] J.J. Palacino, D. Sagi, M.S. Goldberg, S. Krauss, C. Motz, M. Wacker, J. Klose, J.
Shen, Mitochondrial dysfunction and oxidative damage in parkin-deﬁcient
mice, J. Biol. Chem. 279 (2004) 18614–18622.
[177] F.A. Perez, R.D. Palmiter, Parkin-deﬁcient mice are not a robust model of
parkinsonism, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2174–2179.
[178] S. Sato, T. Chiba, S. Nishiyama, T. Kakiuchi, H. Tsukada, T. Hatano, T. Fukuda, Y.
Yasoshima, N. Kai, K. Kobayashi, Y. Mizuno, K. Tanaka, N. Hattori, Decline of
striatal dopamine release in parkin-deﬁcient mice shown by ex vivo autoradi-
ography, J. Neurosci. Res. 84 (2006) 1350–1357.
[179] B. Thomas, R. von Coelln, A.S. Mandir, D.B. Trinkaus, M.H. Farah, K. Leong Lim, N.
Y. Calingasan, M. Flint Beal, V.L. Dawson, T.M. Dawson, MPTP and DSP-4
susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons
in mice is independent of parkin activity, Neurobiol. Dis. 26 (2007) 312–322.
[180] M.I. Ekstrand, M. Terzioglu, D. Galter, S. Zhu, C. Hofstetter, E. Lindqvist, S. Thams,
A. Bergstrand, F.S. Hansson, A. Trifunovic, B. Hoffer, S. Cullheim, A.H. Mohammed,
L. Olson, N.G. Larsson, Progressive parkinsonism in mice with respiratory-chain-
deﬁcient dopamine neurons, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1325–1330.
[181] J. Peng, L. Xie, F.F. Stevenson, S. Melov, D.A. Di Monte, J.K. Andersen, Nigrostriatal
dopaminergic neurodegeneration in the weaver mouse is mediated via
neuroinﬂammation and alleviated by minocycline administration, J. Neurosci.
26 (2006) 11644–11651.
[182] J.K. Mallajosyula, D. Kaur, S.J. Chinta, S. Rajagopalan, A. Rane, D.G. Nicholls, D.A. Di
Monte, H. Macarthur, J.K. Andersen, MAO-B elevation in mouse brain astrocytes
results in Parkinson's pathology, PLoS ONE [Electronic Resource] (2008) 3.
[183] T. Thomas, M. Timmer, K. Cesnulevicius, E. Hitti, A. Kotlyarov, M. Gaestel, MAPKAP
kinase 2-deﬁciency prevents neurons from cell death by reducing neuro-
inﬂammation—relevance in a mouse model of Parkinson's disease, J. Neurochem.
105 (2008) 2039–2052.
[184] Y. Liang, S. Li, Q. Guo, Y. Zhang, C. Wen, Q. Zou, B. Su, Complement 3-deﬁcient
mice are not protected against MPTP-induced dopaminergic neurotoxicity, Brain
Res. 1178 (2007) 132–140.
[185] C.E. Hamill, W.M. Caudle, J.R. Richardson, H. Yuan, K.D. Pennell, J.G. Greene, G.W.
Miller, S.F. Traynelis, Exacerbation of dopaminergic terminal damage in a mouse
model of Parkinson's disease by the G-protein-coupled receptor protease-
activated receptor 1, Mol. Pharmacol. 72 (2007) 653–664.
[186] A. Vroon, B. Drukarch, J.G. Bol, P. Cras, J.J. Breve, S.M. Allan, J.K. Relton, P.V.
Hoogland, A.M. Van Dam, Neuroinﬂammation in Parkinson's patients and
MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis
and differential expression of interleukin-1 receptors in the olfactory bulb,
Exp. Gerontol. 42 (2007) 762–771.
[187] R. Pattarini, R.J. Smeyne, J.I. Morgan, Temporal mRNA proﬁles of inﬂammatory
mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine
model of Parkinson's disease, Neuroscience 145 (2007) 654–668.
[188] L. Qin, X. Wu, M.L. Block, Y. Liu, G.R. Breese, J.S. Hong, D.J. Knapp, F.T. Crews,
Systemic LPS causes chronic neuroinﬂammation and progressive neurodegen-
eration, Glia 55 (2007) 453–462.
[189] J. Jin, F.S. Shie, J. Liu, Y. Wang, J. Davis, A.M. Schantz, K.S. Montine, T.J. Montine,
J. Zhang, Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial
activation and associated neurotoxicity induced by aggregated alpha-synuclein,
J. Neuroinﬂammation 4 (2007) 2.
[190] W. Springer, P.J. Kahle, Mechanisms and models of alpha-synuclein-related
neurodegeneration, Curr. Neurol. Neurosci. Rep. 6 (2006) 432–436.
[191] C.D. Link, Transgenic invertebrate models of age-associated neurodegenerative
diseases, Mech. Ageing Dev. 122 (2001) 1639–1649.
[192] S.K. Singhrao, J.W. Neal, B.P. Morgan, P. Gasque, Increased complement
biosynthesis by microglia and complement activation on neurons in Hunting-
ton's disease, Exp. Neurol. 159 (1999) 362–376.[193] A. Dalrymple, E.J. Wild, R. Joubert, K. Sathasivam, M. Bjorkqvist, A. Petersen, G.S.
Jackson, J.D. Isaacs, M. Kristiansen, G.P. Bates, B.R. Leavitt, G. Keir, M. Ward, S.J.
Tabrizi, Proteomic proﬁling of plasma in Huntington's disease reveals neuroin-
ﬂammatory activation and biomarker candidates, J. Proteome Res. 6 (2007)
2833–2840.
[194] P.L. McGeer, S. Itagaki, E.G. McGeer, Expression of the histocompatibility
glycoprotein HLA-DR in neurological disease, Acta Neuropathol. 76 (1988)
550–557.
[195] E. Sapp, K.B. Kegel, N. Aronin, T. Hashikawa, Y. Uchiyama, K. Tohyama, P.G. Bhide,
J.P. Vonsattel, M. DiFiglia, Early and progressive accumulation of reactive
microglia in the Huntington disease brain, J. Neuropathol. Exp. Neurol. 60 (2001)
161–172.
[196] K. Messmer, G.P. Reynolds, Increased peripheral benzodiazepine binding sites in
the brain of patients with Huntington's disease, Neurosci. Lett. 241 (1998)
53–56.
[197] Y.F. Tai, N. Pavese, A. Gerhard, S.J. Tabrizi, R.A. Barker, D.J. Brooks, P. Piccini,
Microglial activation in presymptomatic Huntington's disease gene carriers,
Brain 130 (2007) 1759–1766.
[198] Y.F. Tai, N. Pavese, A. Gerhard, S.J. Tabrizi, R.A. Barker, D.J. Brooks, P. Piccini,
Imaging microglial activation in Huntington's disease, Brain Res. Bull. 72 (2007)
148–151.
[199] N. Pavese, A. Gerhard, Y.F. Tai, A.K. Ho, F. Turkheimer, R.A. Barker, D.J. Brooks, P.
Piccini, Microglial activation correlates with severity in Huntington disease: a
clinical and PET study, Neurology 66 (2006) 1638–1643.
[200] D.A. Simmons, M. Casale, B. Alcon, N. Pham, N. Narayan, G. Lynch, Ferritin
accumulation in dystrophic microglia is an early event in the development of
Huntington's disease, Glia 55 (2007) 1074–1084.
[201] L. Ma, A.J. Morton, L.F. Nicholson, Microglia density decreases with age in a
mouse model of Huntington's disease, Glia 43 (2003) 274–280.
[202] M. Bjorkqvist, E.J. Wild, J. Thiele, A. Silvestroni, R. Andre, N. Lahiri, E. Raibon,
R.V. Lee, C.L. Benn, D. Soulet, A. Magnusson, B. Woodman, C. Landles, M.A.
Pouladi, M.R. Hayden, A. Khalili-Shirazi, M.W. Lowdell, P. Brundin, G.P. Bates,
B.R. Leavitt, T. Moller, S.J. Tabrizi, A novel pathogenic pathway of immune
activation detectable before clinical onset in Huntington's disease, J. Exp.
Med. 205 (2008) 1869–1877.
[203] M.S. Levine, C. Cepeda, M.A. Hickey, S.M. Fleming, M.-F. Chesselet, Genetic mouse
models of Huntington's and Parkinson's diseases: illuminating but imperfect,
Trends Neurosci. 27 (2004) 691–697.
[204] S.K. Godavarthi, D. Narender, A. Mishra, A. Goswami, S.N. Rao, N. Nukina, N.R.
Jana, Induction of chemokines, MCP-1, and KC in the mutant huntingtin
expressing neuronal cells because of proteasomal dysfunction, J. Neurochem.
108 (2009) 787–795.
[205] E.C. Stack, K.M. Smith, H. Ryu, K. Cormier, M. Chen, S.W. Hagerty, S.J. Del Signore,
M.E. Cudkowicz, R.M. Friedlander, R.J. Ferrante, Combination therapy using
minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice,
Biochim. Biophys. Acta 1762 (2006) 373–380.
[206] X. Wang, S. Zhu, M. Drozda, W. Zhang, I.G. Stavrovskaya, E. Cattaneo, R.J.
Ferrante, B.S. Kristal, R.M. Friedlander, Minocycline inhibits caspase-indepen-
dent and -dependent mitochondrial cell death pathways in models of
Huntington's disease, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10483–10487.
[207] J.K. Ryu, H.B. Choi, J.G. McLarnon, Combined minocycline plus pyruvate
treatment enhances effects of each agent to inhibit inﬂammation, oxidative
damage, and neuronal loss in an excitotoxic animal model of Huntington's
disease, Neuroscience 141 (2006) 1835–1848.
[208] T.M.Woodruff, J.W. Crane, L.M. Proctor, K.M. Buller, A.B. Shek, K. de Vos, S. Pollitt,
H.M. Williams, I.A. Shiels, P.N. Monk, S.M. Taylor, Therapeutic activity of C5a
receptor antagonists in a rat model of neurodegeneration, FASEB J. 20 (2006)
1407–1417.
[209] P. Guidetti, G.P. Bates, R.K. Graham, M.R. Hayden, B.R. Leavitt, M.E. MacDonald, E.
J. Slow, V.C. Wheeler, B. Woodman, R. Schwarcz, Elevated brain 3-hydroxyky-
nurenine and quinolinate levels in Huntington disease mice, Neurobiol. Dis. 23
(2006) 190–197.
[210] P. Guidetti, P.H. Reddy, D.A. Tagle, R. Schwarcz, Early kynurenergic impairment
in Huntington's disease and in a transgenic animal model, Neurosci. Lett. 283
(2000) 233–235.
[211] N. Stoy, G.M. Mackay, C.M. Forrest, J. Christoﬁdes, M. Egerton, T.W. Stone, L.G.
Darlington, Tryptophan metabolism and oxidative stress in patients with
Huntington's disease, J. Neurochem. 93 (2005) 611–623.
[212] C.A. Lemere, M. Maier, L. Jiang, Y. Peng, T.J. Seabrook, Amyloid-beta immu-
notherapy for the prevention and treatment of Alzheimer disease: lessons from
mice, monkeys, and humans, Rejuvenation Res. 9 (2006) 77–84.
[213] E. Sasaki, H. Suemizu, A. Shimada, K. Hanazawa, R. Oiwa, M. Kamioka, I. Tomioka,
Y. Sotomaru, R. Hirakawa, T. Eto, S. Shiozawa, T. Maeda, M. Ito, R. Ito, C. Kito, C.
Yagihashi, K. Kawai, H. Miyoshi, Y. Tanioka, N. Tamaoki, S. Habu, H. Okano, T.
Nomura, Generation of transgenic non-human primates with germline trans-
mission, Nature 459 (2009) 523–528.
